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Abstract 
Rotsinger, Joseph Edward. M.S.  Department of Biochemistry and Molecular Biology M.S 
Program, Wright State University, 2012.  Exploration of YPEL3 response to hormones 
and ability to induce senescence. 
 
     p53 activation through different cellular senescence pathways can trigger cell cycle 
arrest via regulation of p53 target genes.  One such target gene is YPEL3 which is 
expressed upon binding of tumor suppressor protein p53 at its p53 binding sites (Kelley, 
2010).  The ability of p53 to induce YPEL3 gene expression led to the discovery that 
YPEL3 is one of several p53 target genes which induce cellular senescence (Kelley, 2010).  
Additionally YPEL3 can be regulated independently of p53 by estrogen signaling through 
estrogen receptor α (Tuttle, 2011).  The loss of estrogen receptor α or removal of 
estrogen induces YPEL3 gene expression and leads to cellular senescence, indicating 
that estrogen bound to estrogen receptor α represses YPEL3 gene expression (Tuttle, 
2011).  Although YPEL3 induction results in cellular senescence the mechanism by which 
YPEL3 elicits cellular senescence is not well understood.  It is also unknown if other 
steroid hormones, such as testosterone play a role in regulating YPEL3 gene expression  
     To further understand hormone regulation of YPEL3 the first part of this thesis tested 
if testosterone regulates YPEL3 gene expression in MCF7 breast cancer cells and LnCAP 
prostate cancer cells.  Like MCF7 breast cancer cells, LnCAPs cultured in the absence of 
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steroid hormones induced YPEL3 expression indicating that YPEL3 gene expression in 
LnCAPs is repressed by steroid hormones.  This induction of YPEL3 expression was 
blocked by the addition of testosterone to LnCAP cells.  In contrast the addition of 
testosterone to steroid deprived MCF7 cells resulted in YPEL3 induction.  Based on the 
results in LnCAP prostate cancer cells and MCF7 breast cancer cells it appears that 
testosterones effect on YPEL3 gene expression is tissue specific.     
     In part two of this thesis MCF7 and IMR90 cells were employed to determine if over 
expression of YPEL3 leads to increased reactive oxygen species (ROS) levels.  First an 
optimized method for detecting reactive oxygen species levels in breast cancer cells 
using DCFDA was developed.  Utilizing this method, MCF7 human breast cancer cells 
harboring a Tet-On system expressing YPEL3 induced with tetracycline did not show 
increased levels of reactive oxygen species over LacZ expressing MCF7 cells.  
Additionally Infecting MCF7 cells with lentivirus expressing YPEL3 and probing with 
DCFDA showed no increase of ROS levels.  Alternatively IMR90 primary diploid human 
fibroblasts containing a normal repertoire of genes and fully functional pathways were 
infected with lentivirus expressing YPEL3 and also did not show an increase in ROS 
levels.  These results suggest that YPEL3 activates senescence in a ROS independent 
manner.  
     The third part of this thesis was to identify YPEL3 interacting proteins.  Epitope 
tagged YPEL3 proteins obtained from MCF7 tetracycline responsive cells expressing 
YPEL3 were captured from cell extracts by co-immunoprecipitation, followed by elution 
and denaturing.  Denatured proteins were separated by SDS-Page gel electrophoresis 
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and potential protein bands excised for composition analysis by LC/MS/MS.  LC/MS/MS 
analysis identified potential proteins that interact with YPEL3. 
     The cumulative findings of this thesis were designed to aid in the understanding of 
YPEL3 regulation by testosterone and to assist in locating potential downstream targets 
of YPEL3 that may lead to senescence.       
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I. Introduction 
    Compiled data from 1970 to 2002 showed heart disease as the leading cause of death 
in the United States, with cancer ranking second but predicted to overtake heart disease 
as the leading cause of death (Ahmedin, 2005).  This is not due to an increase in the 
number of cancer related deaths; rather it is due to a 52.1% reduction in the number of 
deaths from heart disease, but only a decline of 2.7% in cancer related deaths 
(Ahmedin, 2005).  In 2012 cancer is still projected to be the second leading cause of 
death in the United States (Siegel, 2012).  It is estimated that 1,638,910 new invasive 
cancer cases will be diagnosed with 577,190 cancer related deaths being projected 
(Siegel, 2012).  In males and females prostate cancer and breast cancer both have the 
second highest number of diagnoses respectively, behind only skin cancer (Siegel, 2012).  
Breast cancer is projected to account for 229,060 cases with the mortality rate 
projection being 39,920 in both sexes, with males accounting for 1% of new cases as 
well as deaths (Siegel, 2012).  Prostate cancer is projected to account for 241,740 new 
cases and 28,170 deaths (Siegel, 2012).  With nearly 70,000 projected deaths from 
breast or prostate cancer it becomes even more important to understand the molecular 
basis of the disease and to improve our ability to prevent and detect these cancers 
earlier.
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Breast Cancer 
     Critical to early detection of breast cancer is self or clinical breast exams to identify 
masses that may be forming.  Growth progression of a cancerous mass is dependent on 
the level of the growth stimulating hormone estrogen, and the presence or absence of 
its receptors.  Follicle stimulating hormone is the major stimulator of estrogen 
production, which occurs mainly in the placenta, corpus luteum and developing follicles 
in the ovaries.  Also, to a lesser extent it is produced in granulosa cells of the ovaries, 
adrenal glands, fat cells and the breasts.  After synthesis estrogen diffuses into cells 
where it binds one of two types of nuclear hormone receptors in the cytoplasm and is 
subsequently translocated into the nucleus to impart growth stimulating effects by 
interacting with estrogen response elements of genes.  Nuclear hormone receptors are 
ligand activated transcription factors that bind to specific DNA sequences known as 
hormone response elements and are able to repress or activate transcription of genes 
harboring hormone response elements.  There are two estrogen binding nuclear 
hormone receptors, estrogen receptor α (ER-α) and estrogen receptor β (ER-β), which 
share a high level of sequence homology overall (Dutertre, 2000).  However, they have 
very little sequence homology at one of the two activation of function domains (AF-1) 
which is critical to ER-α’s ability to recruit co-regulatory protein complexes for gene 
expression (Hall, 1999)  ER-β contains a repressor at AF-1 that antagonizes ER-α function 
through dimerization of ER-α and ER-β (Hall, 1999 and Dutertre, 2000).  ER-β also causes 
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competitive repression of ER-α by blocking the ability of ER-α to bind hormone response 
elements of target genes (Leung, 2007).  Another unique characteristic is their different 
gene expression patterns (Couse, 1997).  For example, estrogen receptor α is highly 
expressed in breast tissue, whereas in prostate tissue estrogen receptor β is the main 
receptor expressed (Couse, 1997).  The most extensively studied estrogen receptor is 
ER-α, which imparts pro-growth effects by inducing expression of genes that positively 
regulate cell cycle progression and cell division while repressing genes that are growth 
suppressive (Preston-Martin, 1990).  ER-β is the other nuclear estrogen receptor, 
however its function is not fully known.  ER-β has gone unnoticed until it was recently 
discovered that it may play a role in preventing metastasis of cancerous cells and may 
also have antiproliferative functions (Roy, 2011).  This correlates with findings that 
suggest ER-β positive breast cancers have a better prognosis than ER-β negative breast 
cancers (Leung, 2007).  ER-β also has the ability to increase cell sensitivity to selective 
estrogen receptor modulators (SERMs) by mediating their antiestrogenic properties.  
SERMs elicit an antiestrogenic effect when bound to estrogen receptors by reducing the 
ability of estrogen to signal cell proliferation.  When ER-β binds SERMs it can 
homodimerize with ER-α and modulate ER-α’s ability to induce proliferation (Leung, 
2007).  The levels of ER-β expressed can also be used as a marker to determine how well 
cancer may respond to SERM treatment (Leung, 2007).  All of this taken together shows 
the importance of estrogen levels which may correlate to the rate of estrogen 
dependent tumor progression, therefore the expression of estrogen’s potential target 
genes may serve as good prognostic markers.    
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     Estrogen is known to induce pS2 gene expression which produces a pS2 protein 
(Horiguchi, 1996).  In breast tumors the level of pS2 protein has become a potential 
indicator for predicting treatability, relapse potential and survival (Foekens, 1990).  pS2 
may also be an indicator of early stage breast cancer, since it may not be expressed in 
late stage breast cancer that have become independent of growth stimulation by 
estrogen (Foekens, 1990).  Although high levels of pS2 protein may indicate the 
presence of proliferating breast cancer, it also indicates the presence of ER-α (Foekens, 
1990).  The presence of ER-α decreases the chance of relapse and increase survival due 
to a fully functional estrogen receptor that is treatable (Foekens, 1990).  ER-α positive 
breast cancer may benefit from the ability to block growth progression by inhibiting the 
estrogen receptor with selective estrogen receptor modulators (Park, 2002).   
          In ER+ breast cancer cells, not only are the levels of estrogen important, but also 
the levels of testosterone are important due to aromatase activity in breast cancer 
tissue that can convert androgen substrates into estrogen (Smith, 2003).  Aromatase 
therapy is used clinically to prevent the conversion of testosterone to estrogen, in 
estrogen receptor positive breast cancers (Smith, 2003).  Inhibiting aromatase activity in 
breast cancer is beneficial in two ways, it results in decreased estrogen levels due to the 
loss of testosterone conversion to estrogen, and testosterone may actually have a 
protective effect on male and female breast cancer by inducing cell cycle arrest (Zhou, 
2003, Dimitrakakis, 2003, and Lobaccaro, 1993).  This protective cell cycle arrest by 
testosterone could potentially come from the ability of testosterone bound androgen 
receptors triggering increased p21 expression via an androgen response element 
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located 200 bp upstream of the p21 gene and proximal to the promoter region (Lu, 
1999).  However, testosterone regulation of other genes could play a significant role in 
arresting a cell when treated with testosterone.  
Prostate Cancer 
      Screening for prostate cancer often begins when men receive digital rectal exams as 
part of a yearly physical to locate any irregularities in the back of the prostate.  This 
region of the prostate is where 85% of prostate cancers occur (Chodak, 1989).  If 
irregularities are found one of the next steps is screening for increased levels of a 
specific serine protease, known as Prostate Specific Antigen (PSA), due to the 
correlation of increased PSA levels with testosterone levels and positive prostate cancer 
diagnosis (Thompsons, 2004).  Increased levels of testosterone bound androgen 
receptors will bind the known target gene PSA’s androgen response element located in 
its promoter and signal increased gene expression (Thompsons, 2004).  The potential for 
positive diagnosis of high grade cancer with a Gleason score above seven (scale 0-10, 
with 10 having worst prognosis) increased in men with PSA levels above 4.0 ng/mL of 
blood serum, and significantly increased when PSA levels increased above 10.0 ng/mL of 
blood serum (Thompsons, 2004).  A concern with this test is that obese men tend to 
have decreased PSA levels, which may lead to an increase in false negative results 
(Fowke, 2006).  Additionally there are other stresses such as long distance ambulation, 
ejaculation and aggressive cycling which may lead to increased PSA levels at the time of 
testing (Leibovitch, 2005).  False diagnosis can potentially lead to unnecessary medical 
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procedures, such as biopsy, or chemotherapy.  Prostate cancer may also be associated 
to low free serum testosterone levels and therefore PSA is not an accurate indicator of 
potential prostate cancer (Morgenthaler, 1996).  It was recently discovered that there 
may not be an overall benefit to PSA screening.  When comparing the survival rates of 
prostate cancer patients who participated in PSA monitoring to those who did not have 
PSA screenings there were no survival benefits (Andriole, 2012).  A thirteen year study 
recently concluded that the death rates per 10,000 patients were nearly that same (3.7 
Vs. 3.4) when comparing a group undergoing scheduled PSA screening and digital rectal 
exams to another group which did not undergo scheduled testing.  It is possible that PSA 
screening can false positively diagnose patients with high testosterone levels who do 
not have prostate cancer but have PSA levels in the positive range, or patients can be 
negatively diagnosed with androgen independent prostate cancer (Andriole, 2012). 
Induction of Reactive Oxygen Species During Cellular Senescence. 
   In the mid 1960’s it was reported that in cell culture primary fibroblasts undergo 
growth arrest after a finite number of cellular divisions resulting from the erosion of 
telomeres (Hayflick, 1965).  This finite number of divisions became known as Hayflick’s 
limit (Hayflick, 1965).  After Hayflick’s limit is reached cells enter an arrested state and 
division ceases (Hayflick, 1965).  This growth arrest was coined intrinsic replicative 
senescence.  As telomeres deteriorate the exposed chromosomal ends are sensed as 
DNA damage and a DNA damage response occurs.  The DNA damage response can be 
activated by intrinsic factors such as telomere shortening, as well as extrinsic factors, 
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such as culture conditions, UV or chemical damage.  DNA damage activates ATM and 
ATR, which lead to activation of p53 via phosphorylation by CHK1/CHK2 (Bennett, 2001).  
Activation of p53 increases gene expression of p21 which leads to a transient G1 cell 
cycle arrest and an increase in ROS levels (Passos, 2010).  This increase in ROS maintains 
growth arrest by causing additional DNA damage until the cell is permanently arrested 
(Passos, 2010).  If ROS levels are decreased during transient cell cycle arrest, a cell can 
reenter the cell cycle and begin replication (Lu, 2009).  Not all cellular senescence 
mechanisms are dependent on DNA damage, but rather a third senescence pathway 
exists. 
    Oncogene induced senescence is caused by mitogenic stimuli which can activate RAS 
and lead to increased levels of ROS in both immortalized cells and human diploid 
fibroblasts (Moiseeva, 2009).  The mechanism by which RAS causes increased ROS 
production is not fully understood, however via signaling through the 
RAS/RAF/MEK/ERK signaling pathway, activation of ERK can disrupt the mitochondrial 
membrane, signal cell cycle arrest through p21 and activate NADPH oxidase which 
produces superoxide, a form of ROS (Cagnol, 2010 and Serrano, 1997).  When p21 gene 
expression increases it can also increase ROS production which inhibits phosphatases 
that could inactivate RAS, RAF, MEK or ERK and allows continuous signaling to increase 
p53 levels through ERK (Passos, 2010 and Serrano, 1997).  Cells also trigger increased 
p53 protein levels via RAF inactivation of AKT which causes dephosphorylation of Mdm2 
and blocks Mdm2 mediated degradation of p53 (Cagnol, 2009).  Oncogenic signaling 
through such transcription factors as DMP1 can also activate ARF which blocks MDM2 
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and stabilizes p53, leading to an increase of p53 (Zindy, 1998).  When the level of 
reactive oxygen species overwhelms the natural antioxidant defenses an oxidative stress 
response may occur causing mutations and damage to DNA, which induces a DNA 
damage response (Campisi, 2007).   
    Common to replicative senescence, the DNA damage response pathway and 
oncogene induced senescence is the activation of p53.  p53 is one of the most important 
tumor suppressors, and has been given the moniker “Guardian of the Genome” for its 
ability to actively suppress cellular growth (Lane, 1992).  p53 primarily functions as a 
transcription factor that is kept inactive due to rapid degradation by Mdm2, however 
various cellular stresses can block Mdm2 mediated degradation leading to p53 
accumulation (Louria-Hayon, 2003).  This accumulation causes p53 to activate cell cycle 
inhibitors which induces apoptosis, cellular senescence, or a transient growth arrest that 
can be reversed (Lowe, 2004 and Vousden, 2002).  Common to all tumor formation is 
inactivation of p53 (Itahana, 2001).  When p53 is inactivated it cannot activate its target 
genes and the ability to maintain controlled cellular growth is lost, which is a hallmark of 
tumor progression (Itahana, 2001).     
     Determining the activity of p53 target genes can help explain the functions of p53, 
however there are hundreds of p53 target genes and complex activation patterns that 
are cell type and stress specific (Harms, 2004).  Some of these gene products are 
redundant indicating that not just one p53 target is the basis for p53 dependent 
senescence (Harms, 2004).  Some of the targets of p53 that have been linked to a 
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senescent response include p21, Promyelocytic leukemia PML, Plasminogen Activator 
Inhibitor 1, and DEC1 (Harms, 2004).  Although all of these target proteins elicit cellular 
senescence, their mechanisms are different, PML acts to stabilize p53 by inhibiting 
degradation by Mdm2, Plasminogen Activator Inhibitor 1 can trigger replicative 
senescence and DEC1 mediates p53 dependent G1 cell cycle arrest (Qian, 2010).   This 
signifies the importance of p53 activating many targets to induce growth arrest (Harms, 
2004).  PML, p21, PAI-1 and DEC1 lead to cellular senescence after activation by p53; 
however in the absence of these targets p53 can still elicit a senescence response, which 
indicates that there are other p53 targets that activate senescence and the importance 
of discovering novel p53 targets that cause cellular senescence (Harms, 2004).      
     Recently the YPEL3 gene was reported to be directly activated by p53 and capable of 
eliciting growth arrest in tumor cells (Kelley, 2010).  Based on several assays it was 
determined that YPEL3 induction triggers cellular senescence (Kelley, 2010).  However, 
YPEL3 is not only regulated by p53.  It was recently discovered that in breast cancer cells 
YPEL3 is repressed by estrogen signaling through estrogen receptor α (Tuttle, 2011).  
Blocking estrogen signaling triggered p53 independent cellular senescence (Tuttle, 
2011).  The mechanism by which YPEL3 leads to cellular senescence is not readily 
known.  One goal of this thesis is to explore whether YPEL3 expression triggers ROS. 
Yippee Like 3 (YPEL3) 
     Yippee was discovered in Drosophila via a yeast interaction trap that screened for 
proteins with potential interactions to hemolin of Cecropia Moth, also known by its 
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Binomial nomenclature as Hyalophora cecropia (Roxstrom, 2001).  Hemolin is a 
constitutively active member of the IG superfamily that is expressed at increased levels 
during development and bacterial infection (Roxstrom, 2001).  Increased hemolin levels 
serve an immunological function by binding to bacteria and lipopolysaccharides which 
enhance phagocytosis and activate protein kinase C (Roxstrom, 2001).  Further research 
to determine the role of Yippee binding to hemolin has not been conducted (Roxstrom, 
2001).  Sequencing of subcloned fragments revealed that the Yippee gene has four 
exons which encode a 121 amino acid protein harboring a conserved putative zinc 
binding ring finger motif comprised of four cysteine residues (Roxstrom, 2001).  An 
EMBL database search located a human protein sequence, with 76% sequence 
homology to the Drosophilia Yippee protein, which was later found to harbor the same 
conserved zinc finger motifs found on the Drosophilia Yippee protein (Roxstrom, 2001 
and Honoso, 2004).  This human sequence was later determined to be a paralog of the 
human YPEL family and subsequently named YPEL5 (Honoso, 2004).     
     While characterization of the Yippee gene ceased, comprehensive sequence analysis 
of a 350 kb region of chromosome 22 revealed a Di Georges synteny region in mice 
which contained a novel mouse gene associated with 22q deletion syndrome (Farlie, 
2001).  Deletion at the 22q chromosomal region in humans led to the development of 
craniofacial abnormalities, specifically Di George syndrome, as well as cardiac 
abnormalities and thymic hypoplasia (Scrambler, 2000 and Farlie, 2001).  The novel 
mouse gene, named YPEL1, was subject to a BLAST sequence analysis search and a 
highly homologous human sequence was found (Farlie, 2001).  This sequence was 
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determined to be a human homolog of the mouse YPEL1 gene, which had previously 
been identified as a homolog of the Yippee gene in Drosophilia (Farlie, 2001 and 
Honoso, 2004).    
     In 2003, it was announced that sequencing of the human genome had been 
completed which allowed for sequence analysis of unknown genes or sequences against 
the whole human genome.  A blast search using the human YPEL1 sequence against the 
entire human genome identified four additional human paralogs (Honoso, 2004).  The 
five human paralogs discovered were subsequently named YPEL1-5 after the Yippee like 
gene found in Drosophilia and were found to have high sequence homology from slime 
mold to humans (Honoso, 2004).  Interestingly, using RT-PCR analysis it was discovered 
that YPEL1, YPEL2 and YPEL4 display a restrictive pattern of expression in adult and fetal 
tissue while YPEL3 and YPEL5 are found to be constitutively active in all tissues tested 
(Honoso, 2004). 
     A potential function for YPEL3 was discovered when Murine Small Unstable Apoptotic 
Protein (SUAP), which has detrimental effects on actively dividing cells, was determined 
to be the mouse homolog of human YPEL3 (Kelley, 2010).  Prior to making this 
connection it was discovered that mouse YPEL3 gene has 100% sequence homology to 
human YPEL3 indicating a potential orthologous gene (Hosono, 2004).  SUAP (mouse 
YPEL3) in murine myeloid precursor cells suppresses IL-3 dependent proliferation and its 
overexpression induced apoptosis following IL-3 withdraw (Baker, 2003).  The 
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detrimental effect SUAP (mouse YPEL3) has on proliferating cells suggests human YPEL3 
may play a role in blocking cell cycle progression. 
    Interest over the YPEL3 paralog increased due to microarray analysis linking YPEL3 as 
a potential target of p53 (Heminger, 2009).  Increasing the level of p53 by knockdown of 
the p53 negative regulators HdmX and Hdm2 induced YPEL3 gene expression when 
compared to cells with fully functional HdmX and Hdm2  (Heminger, 2009).  The YPEL3 
gene was found to be induced in a p53 dependent manner in the presence of DNA 
damaging agents (Kelley, 2010).  The activation of a cotransfected luciferase reporter 
vector harboring three putative p53 half sites with a wild type p53 indicated that p53 
can directly bind to the YPEL3 gene promoter when damage is induced (Kelley, 2010).  A 
chromatin immunoprecipitation assay further proved that p53 binds the YPEL3 gene 
promoter in vivo (Kelley, 2010).  Taken together, it was determinde that YPEL3 acts 
downstream of p53 (Kelley, 2010).  
     Since YPEL3 gene expression is regulated by p53, and p53 is known to induce growth 
arrest, potential functions of YPEL3 were examined.  Increasing YPEL3 gene expression 
in a p53 independent manner indicated growth suppression which was shown by 
decreased levels of colonies in a colony formation assay and growth arrest indicated by 
an increase in cells in the G1 or S phase (Kelley, 2010 and Berberich, 2011).  Growth 
arrest in cells overexpressing YPEL3 was determined to be cellular senescence; which 
was confirmed by an increase in β-Galactosidase levels, a hallmark of cellular 
senescence (Kelley, 2010).  This indicates that human YPEL3 can cause cellular 
senescence independent of p53 (Kelley, 2010).  Although it was previously predicted 
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that YPEL3 may lead to apoptosis, as does mouse YPEL3, no increase in apoptotic cells 
were seen when YPEL3 gene expression was increased (Kelley, 2010).  However, it was 
noted that both mouse and human YPEL3 are rapidly degraded by ubiquitin mediated 
proteasomes (Baker, 2003 and Kelly Miller Personal Communication).   
 
YPEL3 Is Inactivated In Human Cancers. 
    Due to growth suppressive effects of YPEL3 it was predicted that YPEL3 is 
downregulated in human cancers since cancer exhibits unregulated growth progression.  
As expected, in colon, lung and ovarian tumors YPEL3 was found to be downregulated, 
hence suppressing its growth repressive mechanism (Kelley, 2010 and Tuttle, 2011).      
     Further analysis of various cell lines uncovered that YPEL3 downregulation can occur 
epigentically through hypermethylation of a 950bp CpG island found near the promoter 
and histone acetylation, as well as through a p53 independent pathway involving 
estrogen signaling via estrogen receptor α (Kelley, 2010 and Tuttle, 2011).  When 
estrogen is bound to estrogen receptor α it elicits a suppressive effect on YPEL3 gene 
expression (Tuttle, 2011).  Estrogen receptor α is imperative to YPEL3 gene suppression 
because following ER-α knockdown YPEL3 gene expression increases, even in the 
presence of estrogen (Tuttle, 2011).  However, upon the removal of estrogen in 
estrogen receptor positive cells an increase in YPEL3 gene expression is also seen 
indicating the importance of estrogen as well as its receptor in gene suppression.  The 
growth suppressive effects of an estrogen antagonist such as selective estrogen 
receptor modulator Tamoxifen is able to induce YPEL3 gene expression (Tuttle, 2011).   
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     The culmination of these findings, coupled with the growth promoting activities of 
testosterone led us to explore YPEL3 gene expression regulation by testosterone in 
breast and prostate cancer cells.  It has also led to studies that examine the downstream 
effects of YPEL3 that elicit senescence, given that the senescence pathway that is 
activated upon activation of YPEL3 is not well understood.  One potential mechanism 
that was examined in this thesis was whether YPEL3 triggered an increase in intracellular 
ROS.    
      
Purpose 
     The purpose of this study is to further examine the effects of hormone regulation on 
YPEL3 gene expression, determine if increased YPEL3 gene expression can cause ROS 
production, and find potential proteins that interact with YPEL3.  It has been previously 
shown that increased YPEL3 levels induce cellular senescence; however this pathway is 
not yet fully understood.  In the first objective of this thesis, which is derived from 
previous work revealing the ability of estrogen to suppress YPEL3 in breast cancer, the 
effects of testosterone on LnCAP cells and MCF7 cells were examined.  We have 
previously seen that overexpressionof YPEL3 induces cellular senescence and wanted to 
determine if this may have any correlation to Reactive Oxygen Species production.  For 
the second part of this thesis the hypothesis that YPEL3 expression leads to increased 
ROS production was tested in IMR90 and MCF7 cells.  The third part of this thesis will 
present preliminary findings of potential proteins that interact with the YPEL3 protein.  
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The results from this thesis may provide insight into new potential therapeutic targets 
and get us closer to identifying the pathway by which YPEL3 induces cellular senescence.   
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II. Materials and Methods 
Cells and Reagents 
     LnCAP cells derived from a prostate adenocarcinoma were grown in RPMI 1640 
media supplemented with 10% fetal bovine serum (FBS) and 10 μg/mL gentamycin.  
MCF7 breast carcinoma cells and IMR90 primary human diploid fibroblasts (less than 20 
passages) were grown in Dulbeco’s Modified Eagle Medium (DMEM) supplemented with 
10% FBS and 10 μg/mL gentamycin (complete media).  All cell lines were purchased 
from American Type Culture Collection.   
     Reagents used to treat cells include doxocycline or tetracycline (Clontech), β-estradiol 
(Sigma), and testosterone (Sigma). 
Virus Infections     
       Lentivirus that had previously been produced were thawed and used to infect MCF7 
cells, as well as IMR90 cells (Table 1).  Cells were plated at a minimum density of 50K to 
a maximum density of 200k in complete media.  After 24 hours the complete media was 
removed and a mixture containing viral supernatant (1 mL), complete media (1 mL) and 
Polybrene (6 µg/mL) was added.  The infected cells were incubated for 24 hours before 
being refed with complete media.  After an additional 24 hours antibiotic selection was 
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Lentiviral Plasmid Antibiotic 
Resistance 
MCF7  IMR90 
pLenti4-YPEL3-V5 Zeocin 750 
µg/mL 
100 
µg/mL 
pLenti6-RAS Blasticidin 6 µg/mL 5 µg/mL 
pLenti6-GFP Blasticidin 6 µg/mL 5 µg/mL 
 
Table 1: Lentiviral Plasmid and Antibiotic Doses for MCF7 and IMR90 cell lines.  
     Lowest dose of selecting agent needed to eradicate cells not expressing a resistance 
gene.  Blasticidin and Zeocin were obtained from Invitrogen.  (Experiments conducted 
by Kate Heminger)  
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added and selection continued until no viable cells were left in a parallel mock infected 
plate (Table 1).  The lowest dose of Zeocin or Blasticidin used for antibiotic selection had 
previously been determined by kill curve experiments in MCF7 and IMR90 cells (Table 
1).  Antibiotic selection exposure ranged from 7 to 12 days, after which cells were refed 
with complete media for 24 to 72 hours.  
 Generating and Detecting Intracellular Reactive Oxygen Species  
     IMR90 and MCF7 cells were plated at a density of 200k cells per well in a six well or 6 
cm culture plate.  To elicit reactive oxygen species (ROS) activity, after 24 hours cells 
were treated with 10 μM of Hydrogen Peroxide (Cumberland Swan Inc) in DMEM + FBS 
for 2 hours.  Media was removed and adherent cells were rinsed with Dulbeco’s 
Phosphate Buffered Saline (DPBS).  DPBS was removed and 1mL of DPBS was added to 
each well along with 8 μM of DCFDA (D399 H2DCFDA and C6827 CM-H2DCFDA  
Invitrogen) reconstituted in Dimethyl Sulfoxide (DMSO).  After preliminary studies a 
switch from H2DCFDA to CM-H2DCFDA was made due to availability, but this was 
beneficial due to better retention in live cells.  The dye (H2DCFDA or CM-H2DCFDA) was 
added to six well or 6 cm culture plates.  Cells were incubated at 37oC for 30 minutes 
wrapped in aluminum foil to avoid light induced oxidation.  Adherent cells in 6 well or 6 
cm culture plates were rinsed with DPBS, scraped and resuspended in DPBS in 5 mL snap 
cap tubes for flow cytommetry. 
     Cells undergoing flow cytommetry analysis were scraped in DPBS into 5 mL snap cap 
tubes and wrapped in aluminum foil to deter light induced oxidation.  Flow cytommetry 
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was performed on a BD Accuri C6 Personal Flow Cytometer with a run limit of 30,000 
events and using the preset medium fluidics setting of 35 µL per minute and a core size 
setting of 16 µm.   Results were analyzed using CF-20 CFlow Plus Analysis Software and 
FCS Express version 3 or 4(De Novo Software).  Histogram plots were analyzed in log 
scale on the X-axis by setting it to FL1-A and linear scale on the Y-axis by setting to cell 
count.  
RNA Isolation 
     Cells were rinsed 1 time with Dulbecco's Phosphate Buffered Saline (DPBS) and then 
lysed with TRK lysis buffer supplemented with 2% β-mercaptoethanol.  The lysate was 
transferred to an Eppendorf tube and frozen at -80oC until needed.  After thawing, 1 
volume of 70% ethanol was added to each sample followed by vortexing.  RNA was 
isolated following the e.Z.N.A. Total RNA kit (Omega Bio-Tek) protocol.  RNA was eluted 
in 40μL of DEPC water that had been heated to 70oC and incubated on the spin column 
pad for 5 minutes.  RNA quantification was performed on a NanoDrop DN-1000 
spectrophotometer with RNA purity being determined by the absorbance ratio at 260 
nm and 280 nm.  A ratio of 1.8-2.1 signified good quality RNA.    
Reverse Transcription 
     CDNA was created by mixing 500 ng of RNA, 4 μL of qScript cDNA supermix (Quanta 
Biosciences Inc.) and enough sterile distilled water to bring the reaction to a total of 20 
µL.  The reaction was incubated for 5 minutes at 25oC, 30 minutes at 42oC , 5 minutes at 
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85oC followed by indefinite holding at 4oC (ABI 2700).  The cDNA was then diluted with 
200 µL of sterile distilled water prior to quantitative PCR. 
Taqman Base PCR 
     The ABI 7900HT sequence detection system (Applied Biosystems) was used to 
perform quantitative real time PCR in quadruplicate on a 96 well microtiter plate.  The 
20 μL Taqman based PCR reaction was prepared by combining 9 μL of the diluted cDNA 
mix with a 11 μL master mix containing 10 μL of 2X Taqman Universal PCR master mix 
(Applied Biosystems) and 1 μL of the appropriate 20x Taqman Assay-on-Demand Gene 
Expression product (Applied Biosystems).  The reactions were then subjected to 2 
minutes at 50°C, 10 minutes at 95°C followed by 40 cycles of 15 seconds at 95°C and 1 
minute at 60°C.  Target gene expression was normalized to GAPDH expression and 
analysis of gene expression was performed using SDS 2.2.2 software (ABI) setting a 
confidence interval of 95%.  Outlier Ct values were assessed based on the ΔCtSD values.  
Outliers were automatically and manually removed to improve the RQ minimum and 
maximum range. 
Protein Extraction 
     Cells were rinsed with 5 mL of DPBS and harvested by scraping into 5 mL of fresh 
DPBS.  Cellular suspensions of five 15 cm plates were combined into a 50 mL test tube 
and pelleted by centrifugation at 4000 RPM for 2 minutes.  The supernatant was 
carefully drawn off the pellet.  Pellets were stored at -80oC until needed.  Based on the 
cell pellet size, five volumes of lysis buffer (50 mM Tris pH 8.0, 5mM EDTA, 150nM NaCl, 
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0.5% Nonident p-40, 1mM phenylmethanesulfonylfluoride (Sigma), 1mM Dithiothreitol 
(Sigma) and Protease Inhibitor Coctail (Sigma)) were added and the frozen pellet was 
allowed to thaw on ice.  The pellet was gently resuspended and transferred to a new 50 
mL screw cap tube for centrifugation in a 4oC environment at 11,000 RPM (15,000G) for 
15 minutes.  The soluble protein fraction was transferred from the insoluble material to 
a clean 15mL test tube.  A Bradford Protein Assay was used to determine the protein 
concentration of the cell extract.   Bovine Serum Albumin acetylated (BSA) (Promega) 
was used to generate a standard curve at by adding 2 μg, 5 μg or 10 μg to 800 μL of 
sterile distilled water (SDW) and 200μL of Bradford Protein Assay Dye Reagent (Bio-
Rad).  Unknown protein concentrations were determined by adding 5 μL of protein that 
had been diluted tenfold to 800 μL of SDW and 200 μL of Bradford Protein Assay Dye 
Reagent.  The samples and standards were transferred to plastic cuvettes and 
absorbance was measured at 595nM on either a Genesys 5 Spectrophotometer or 
Genesys 6 Spectrophotometer (Thermospectronic).  The protein samples concentrations 
were determined by comparing their absorbencies to the standard BSA absorbencies.   
Co-Immunoprecipitation 
     A total of 100 mg of protein obtained by the protein extraction method was moved 
to a new test tube diluted to 10 mL with lysis buffer.  To each reaction either 40 μg (80 
μL) of Agarose Immobilized Rabbit Anti V5 beads (Bethyl), or 80 μL Anti V5 Agarose Gel 
produced in mouse (Sigma) was added and allowed to incubate overnight at 4oC.  Each 
sample was centrifuged at 4000 rpm for 8 minutes at 4oC.   Lysis buffer was removed by 
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pipetting and resuspended in 6 mL of fresh lysis byffer followed by incubation for 5 
minutes at 4oC on a rotating platform.  This washing process was repeated 6 times and a 
fraction (F#) of each wash was saved. Following the washes, the beads were transferred 
to a 1.5 mL Eppendorf test tube by adding 1 mL of lysis buffer to the beads and 
resuspending.  The beads were centrifuged in a 4oC microfuge at 10,000 rpm for 5 
minutes and excess lysis buffer was removed from the bead pellet.  At this point the 
bound proteins were either eluted by adding 50 μL of 1X SDS Page Running Buffer to the 
beads and heating for 5 minutes at 37oC, or 0.8 mg (200 μL) of competing V5 peptide 
(Sigma) added to the beads, inverted at 4oC for 5 minutes, 4oC cold centrifuged for 5 
minutes at 10,000 rpm and repeated to obtain 2 eluted fractions (EF#).  When samples 
were eluted with V5 peptide after the second elution the beads were resuspended in 50 
μL of 2X SDS Dye and heated to 70oC for 5 minutes.  The beads were centrifuged in a 4oC 
microfuge at 10,000 rpm for 5 minutes and the bead fraction was removed from the 
bead pellet.  The 2 eluted fractions (EF) from each cell set were combined and 
concentrated by adding 3.6 mL of lysis buffer to the elutions and loading into an Amicon 
Ultra Centrifugal Filter 3k molecular weight ultracell (Millipore) which was centrifuged at 
3600 g for 70 minutes at 4oC.  Alternatively, the EF was concentrated by loading each 
fraction into a Microcon Ultracel YM-10 centrifugal filter (Sigma) which was centrifuged 
at 10,000 RPM for 10 minutes at 4oC.  For both concentration methods the flow through 
was removed and additional lysis buffer was added to desalt the proteins.  The proteins 
were concentrated in a volume of 20 µL of Lysis buffer.  To the retentate, 20 µL of lysis 
buffer was added and vigorous pipetting was used to loosen proteins from the 
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membrane.  The retentate was combined with an equal amount of 2X SDS loading Dye 
and stored at -80oC until further use.          
SDS-PAGE Electrophoresis 
     Protein extracts were combined with an equal volume of 2X SDS loading dye (1X = 60 
mM Tris, pH7.6, 2% SDS, 10% glycerol) and loaded into either a large 12% SDS-Page gel 
with a 4% stacking gel run in a V16 electrophoresis apparatus (Gibco Bethesda Research 
Laboratories) with 1X SDS running buffer (25 mM Tris pH 8.3, 250 mM glycine, 0.1% SDS) 
at 150V for approximately 30 minutes then 250V for approximately 1.5 hours , or a 
precast 8-16% Precise Protein Tris Hepes Gradient Gel (Thermo Scientific) run in BupH 
Tris Hepes SDS running buffer (Thermo Scientific), reconstituted in deionized water, for 
approximately 45 minutes at 150V using an Owl P8D (Owl Separation Systems Inc).   
Western Blot 
     Denatured proteins were transferred from the SDS-PAGE gel to polyvinylidene 
difluoride (PVDF) membrane (Millipore), that had been presoaked in 100% methanol for 
15 seconds and then transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol, pH 
8.3) for 5 minutes, via a Bio-Rad Mini Protean 2 transfer system for 1 hour at .5 Amps in 
transfer buffer.  After transfer the PVDF membrane was dried and then placed in PBS 
blocking buffer (1X PBS, 5% non-fat dry milk (NFDM), 0.1% Tween-20) for 24 hours on a 
moving platform at 4oC.  Primary antibody (monoclonal V5) (Sigma) was added at a 
concentration from 1:1000-1:5000 in diluted PBS blocking buffer (1:10) for a minimum 
of 5 hours (Room Temperature) and a maximum of 24 hours (4oC).  The PVDF 
 
24 
 
membrane was washed 5 times for 15 minutes each in diluted PBS blocking buffer.  The 
secondary antibody with conjugated horseradish peroxidase enzyme (Goat Anti Mouse) 
(Promega) was added at a concentration of 1:2500 in diluted PBS blocking buffer and 
allowed to incubate for 1 hour at room temperature.  The PVDF membrane was again 
washed 5 times for 15 minutes each in diluted PBS blocking buffer and exposed to Super 
Signal West Pico Chemiluminesence (Thermo Scientific) for 2-3 minutes.  
Chemiluminescent images of the blot were taken in a FUJI FILM LAS 4000 image reader 
and the images were were visualized using Fujifilm Multi Guage software.  To reprobe 
the PVDF membrane, it was first stripped with two 30 minute treatments in Western 
Strip Buffer (25 mM glycine, 1% SDS, pH 2.0).  The membrane was rinsed extensively in 
DPBS and then reblocked with DPBS blocking buffer before repeating the above 
protocol.  
Colloidal Blue and Silver Staining     
     SDS-Page protein gels were fixed in 40% methanol and 5% acetic acid overnight on a 
shaker.  Gels were then stained following the NuPage Bis Tris protocol contained in the 
Novex Colloidal Blue Stain kit (Invitrogen).  To silver stain a gel it was first fixed in 40% 
ethanol and then one of the following three methods were employed.  The first method 
was to follow the protocol from the Bio-Rad Silver stain kit (Bio-Rad).  The second 
method exposed the gel 2 times to 10% glutaraldehyde for 3 minutes each.  The gel was 
then placed in 200 nM Dithiothreitol for 10 minutes, followed by .1% silver nitrate for 15 
minutes.  The gel was rinsed 2 times with sterile distilled water (SDW) for 1 minute each 
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to remove excess silver nitrate.  Formalin (0.4%) plus 2% sodium carbonate was used to 
develop the gel with an exposure time between 4 to 8 minutes.  Development of the gel 
was stopped by placing it in 1% acetic acid.  The third method fixed the gel in 20mg/mL 
sodium thiosulfate for 2 minutes.  The gel was then rinsed in SDW twice for one minute 
each.  After rinsing, the gel was exposed to .1% silver nitrate for 30 minutes.  The excess 
silver nitrate was then removed by washing twice with SDW for 1 minute each.   The gel 
was developed with .04% formalin plus 2% sodium carbonate with an exposure time 
between 4 to 8 minutes.  Acetic acid (1%) was used to stop development of the gel 
indefinitely. 
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III. Hormone Regulation of YPEL3 
The effects of testosterone on YPEL3 Expression in LnCAPs 
     It has previously been shown in estrogen receptor positive MCF7 breast cancer cells 
that growth in the presence of estrogen leads to a repression of YPEL3 gene expression 
(Tuttle 2011).  In addition to estrogen receptors, MCF7 cells also harbor androgen 
receptors (Ortmann, 2002).  However, the effects of testosterone on YPEL3 gene 
expression are unknown in MCF7 cells.  Also unknown are the effects that steroid 
hormones play on YPEL3 gene expression in non breast cancer cell lines.  Steroid 
hormones, which include estrogen, progesterone and testosterone, diffuse into cells 
where they bind their respective cytoplasmic receptor and are translocated into the 
nucleus to impart growth stimulation or inhibition.  LnCAP cells, which are derived from 
human prostate adenocarcinoma, are a hormonally responsive cell line containing both 
androgen and estrogen receptors (Horoszewicz, 1983).  The presence of estrogen or 
testosterone has been shown to have growth stimulating effects on LnCAPs 
(Castagnetta, 1995 and Kampa, 2002)           
     To determine whether hormones regulate YPEL3 gene expression in prostate cancer 
cells, LnCAP cells were grown in complete media or charcoal stripped serum (CSS) for up  
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Figure 1: YPEL3 Expression Is Induced In LnCAP Cells Grown In CSS. 
     LnCAP cells were plated in complete media for 24 hours before being switched to 
CSS, or refed with complete media.  RNA from cells grown in complete media was 
isolated 24 hours after the first feeding (CM).  Cells grown in charcoal stripped serum 
were either fed every 24 hours (CSS *), or the media remained unchanged (CSS). RNA 
was isolated after 24, 48 and 72 hours.  YPEL3 mRNA levels were analyzed using RT-PCR 
normalized to GAPDH mRNA levels.  Error bars represent the 95% confidence intervals 
resulting from triplicate assays for both YPEL3 and GAPDH expression. 
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to a total of 72 hours (Figure 1).  Growing cells in CSS, which is devoid of all hormones as 
well as other lipophilic compounds including certain growth factors and cytokines, gives 
the ability to analyze the impact of hormone removal on YPEL3 gene expression.  LnCAP 
cells were grown in complete media or CSS media for 24, 48 or 72 hours prior to total 
RNA isolation and RT-PCR analysis for YPEL3 mRNA levels.  YPEL3 gene expression 
increased 2 fold in the LnCAP cells cultured in CSS after 24 hours and continued to 
increase up to 4.7 fold at 72 hours when fed every 24 hours.  Regardless of feeding 
schedules if the LnCAP cells were fed fresh CSS media every 24 hours or not there is an 
induction of YPEL3 gene expression caused by culturing LnCAP cells in CSS media, when 
compared to complete media. 
     Having demonstrated that growing LnCAP cells in CSS media induces YPEL3 
expression the next series of experiments tested the effect of administering 
testosterone on YPEL3 gene expression.  Testosterone is an important regulator of cell 
cycle progression and proliferation in LnCAP cells, however it is unknown if testosterone 
plays a role in regulating YPEL3 gene expression.  By performing a dose response the 
effects of various testosterone doses on YPEL3 gene expression was determined.  LnCAP 
cells were initially grown in complete media for 24 hours then switched to CSS and 
varying doses of testosterone (0-100 nM) were administered to the CSS media (Figure 
2).  RNA was isolated 24 hours post testosterone treatments and mRNA levels of PSA 
and YPEL3 were assessed by RT-PCR.  PSA was used as a positive control since its 
induction by testosterone in LnCAP cells has been previously reported (Kampa, 2002).   
As expected the addition of testosterone resulted in a dose-dependent induction of 
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Figure 2: YPEL3 is repressed in LnCAP cells in the presence of Testosterone. 
     LnCAP cells were grown in complete media for 24 hours before being switched to 
charcoal stripped serum.  After 24 hours testosterone was added at doses of 2, 5, 10, 
25, and 100 nM to the CSS media.  RNA was isolated 24 hours after testosterone 
exposure.   (B) YPEL3 and (A) PSA mRNA levels were analyzed using RT-PCR normalized 
to GAPDH mRNA levels.  Error bars represent the 95% confidence intervals resulting 
from triplicate assays for PSA, YPEL3 and GAPDH expression.  
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PSA gene expression (Figure 2A).  In contrast, YPEL3 showed a consistent 80% reduction 
in gene expression across the range of testosterone treatments (Figure 2B).  These 
results suggest that YPEL3 expression is repressed by testosterone in LnCAP cells. 
     Prostate cells normally do not possess aromatase activity which converts androgens 
to estrogen, however upon conversion to a malignant state; LnCAP prostate cells begin 
to express aromatase (Ellem, 2004).  By monitoring the expression of pS2, which is a 
target gene of estrogen, we could indirectly assess whether testosterone was being 
converted to estrogen in LnCAP cells.  LnCAPs were grown in CSS to induce YPEL3 and a 
testosterone time course using 10 nM was set up (Figure 3).  A dose of 10 nM was 
chosen because not only was it shown in the dose response from Figure 2 to give the 
largest repression of YPEL3 gene expression and the second highest PSA induction, but 
also because aromatase activity in LnCAP cells has been shown to not exceed a 
conversion rate of .54 nM of testosterone to estrogen over 72 hours (Castagnetta, 
1997).  By saturating the aromatase enzymes it can be determined if testosterone has 
an impact on YPEL3 gene expression, or if its conversion to estrogen potentially 
regulates YPEL3 gene expression.  Higher doses of testosterone may give a marginally 
higher PSA induction that is not statistically different from 10 nM, but higher doses do 
not repress YPEL3 gene expression as well.  Isolating total RNA at hourly time points of 
2, 4, 8, 24, and 48 hours followed by quantification of mRNA levels for YPEL3 and PSA by 
RT-PCR analysis, was used to generate a time course curve to determine PSA and YPEL3 
gene expression levels.  Analysis of PSA gene expression by time course curve revealed 
that MCF7 cells grown in the presence of 10 nM testosterone induced PSA gene   
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Figure 3: YPEL3 Repression is inversely related to PSA expression in LnCAP Cells 
exposed to 10 nM Testosterone for 48 hours.  LnCAP cells were plated in complete 
media for 24 hours before being switched to CSS.  After 24 hours 10 nM testosterone 
was added to the CSS media.  RNA was isolated at 2, 4, 8, 24 and 48 hour timepoints. 
YPEL3, PSA and PS2 mRNA levels were analyzed using RT-PCR normalized to GAPDH 
mRNA levels.  Error bars represent the 95% confidence intervals resulting from triplicate 
assays for PSA, YPEL3, PS2 and GAPDH expression. 
*Outlying data at 8 hours was removed for YPEL3.  
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expression increases up to 24 hours before PSA gene expression began to return to 
baseline levels.  Alternatively, testosterone (10 nM) caused maximal repression of YPEL3 
gene expression at 24 hours and continued maximal repression at 48 hours.  At 24 hours 
there was a 12 fold increase in PSA, which was the highest, and also a 38% reduction in 
YPEL3, which was the largest reduction.  However, at 48 hours there was a 4 fold 
induction of PSA, which may be attributed to testosterone degradation (t½= 2-4 Hr) as 
well as the turnover and synthesis rate of androgen receptors (Eckert, 1984).  Levels of 
pS2 mRNA were also quantified by RT-PCR, revealing no change in pS2 gene expression 
in LnCAPs over 48 hours, suggesting that testosterone is not being converted to 
estrogen under these conditions.  
     Testosterone replacement therapy can have beneficial effects when administered in 
the event of Hypogonadism, or low testosterone levels.  However, if an androgen 
receptor positive prostate cancer is present testosterone may lead to a more aggressive 
cancer.   
     After a prostatectomy, which removes the prostate, testosterone replacement 
therapy is used to maintain lost testosterone production; however testosterone may 
also induce growth progression of metastatic prostate cancer cells that have evaded 
prostatectomy and chemotherapeutic treatment.  The addition of testosterone to 
LnCAP prostate cells has a repressive effect on YPEL3 gene expression which may lead to 
cell cycle progression.  This strengthens the idea that testosterone replacement therapy 
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is not the best choice when androgen responsive prostate cancer is suspected, due to its 
ability to repress expression of YPEL3.  
The effects of Testosterone on YPEL3 Expression in MCF7 Cells 
     The progression of estrogen receptor positive breast cancer has been linked to 
estrogen induced cell proliferation (Katzenellenbogen, 1987).  Testosterone on the 
other hand has been shown to inhibit growth in androgen receptor positive breast 
cancer cells (Ortmann, 2002).  Cells that harbor both the androgen and estrogen 
receptor like MCF-7 cells may proliferate in the presence of estrogen but proliferation is 
inhibited in the presence of testosterone (Ortmann, 2002).  The level of inhibition by 
testosterone is slightly less in cells with aromatase activity due to its ability to convert 
testosterone to estrogen (Ortmann, 2002).  However, unlike LnCAP cells aromatase 
expression is repressed at the transcriptional level in MCF7 breast cancer cells 
(Castagnetta, 1997 and Zhou, 1993).   
     With the knowledge that YPEL3 is repressed in MCF7 cells in the presence of estrogen 
we set forth to determine how testosterone impacted YPEL3 expression in MCF7 cells 
when given alone or in combination with estrogen.  MCF7 cells were utilized since they 
contain estrogen and androgen receptors (Horwitz, 1975).  MCF7 cells grown in CSS 
were exposed to 1nM estrogen, 5nM testosterone, or a combination of both (Figure 4).  
Estrogen was chosen at a dose of 1 nM due to previous research that shows no further 
repression of YPEL3 in MCF7 breast cancer cells at higher doses (Tuttle, 2011).  A dose of 
5 nM testosterone was chosen because it was found to be near, or slightly more than  
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Figure 4:  Testosterone Induction and β-estradiol Repression of YPEL3 in MCF7 Cells.  
MCF7 cells were plated in complete media for 24 hours before being switched to CSS.  
The media was changed to CSS with the addition of either 1 nM Estrogen, 5 nM 
testosterone, or a combination of Estrogen (1 nM) and testosterone (5 nM). RNA was 
isolated after 24 hours.  YPEL3 mRNA levels were analyzed using RT-PCR normalized to 
GAPDH mRNA levels.  Error bars represent the 95% confidence intervals resulting from 
triplicate assays for both YPEL3 and GAPDH expression. 
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 the threshold of high to normal testosterone production (Schroder, 1998).   As 
expected, MCF7 cells treated for 24 hours with 1 nM of estrogen showed a 25% 
repression of YPEL3 gene expression (Figure 4).  MCF7 cells exposed to 5nM of 
testosterone resulted in a 5.9 fold increase in YPEL3 mRNA levels, when compared to 
CSS control, which is opposite of what was observed in LnCAP cells.  Treatment with 
both estrogen (1 nM) and testosterone (5 nM) showed a slight increase in YPEL3 gene 
expression when compared to CSS control, suggesting that the two steroids have 
opposing effects on YPEL3 mRNA expression. 
     To expand on the results obtained in Figure 4 comparing testosterone and estrogen 
combination in MCF7 cells, a dose response curve with 1 nM estrogen and various doses 
of testosterone was performed.  By growing MCF7 cells in CSS media and adding various 
doses of testosterone in addition to 1nM estrogen a dose response can be generated.   
MCF7 cells were grown in CSS media for 24 hours before the addition of testosterone 
(0.5 -10 nM) combined with 1 nM estrogen (Figure 5).  Total mRNA was isolated after 24 
hours, and as expected the CSS sample showed a near 2 fold induction of YPEL3 gene 
expression.  The addition of 0.5 nM testosterone and 1 nM estrogen represses YPEL3 
gene expression back to levels that are statistically the same as MCF7 cells grown in 
complete media.  When testosterone and estrogen are administered both at 1 nM there 
is an increase in YPEL3 gene expression relative to MCF7 cells grown in complete media, 
but there is no statistical difference when compared to MCF7 cells grown in CSS.  
However, YPEL3 gene expression increases in a dose dependant manner as testosterone 
levels are increased above 1 nM.  A combination of 5 nM testosterone and 1 nM  
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Figure 5: In MCF7 Cells YPEL3 is Induced in the Presence of Increasing Doses of 
Testosterone.  MCF7 cells were plated in complete media for 24 hours before being 
switched to CSS.  After 24 hours of growth in CSS media MCF7 cells were exposed to 1 
nM estrogen combined with either 0.5 nM, 1 nM, 5 nM, or 10 nM of testosterone.  RNA 
was isolated after 24 hours.  YPEL3 levels were analyzed using RT-PCR normalized to 
GAPDH mRNA levels.  Error bars represent the 95% confidence intervals resulting from 
triplicate assays for both YPEL3 and GAPDH expression. 
 
 
 
 
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
4 
4.5 
5 
CM CSS 0.5T + 1E2 1T + 1E2 5T + 1E2 10T + 1E2 
Ex
p
re
ss
io
n
 
Hormone Doses [nM] 
 
38 
 
 estrogen yielded a 3 fold increase in YPEL3 gene expression when compared to 
complete media, and the first statistically significant increase when compared to MCF7 
cells grown in CSS media.  A further increase in YPEL3 gene expression to 4 fold was 
seen when 10 nM testosterone was combined with 1nM estrogen.  This indicates there 
may be a counteracting effect between testosterone and estrogen. 
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IV. Reactive Oxygen Species is not produced during YPEL3 induction. 
     Cellular senescence is the irreversible loss of cellular division which can be mediated 
by an increase in the level of reactive oxygen species (ROS) (Passos, 2010).   A cell 
normally produces ROS as a byproduct of cellular respiration; however it has 
mechanisms to convert potentially damaging reactive oxygen species to more stable 
forms leading to minimal DNA damage (Nohl, 2004).  A cell may regulate its ROS levels 
by many different mechanisms, some are known, and others are novel mechanisms 
being discovered.  Recently our laboratory discovered that YPEL3 could trigger cellular 
senescence when over expressed, however the mechanism leading to this senescence is 
currently unknown (Kelley, 2010).    
      By adding hydrogen peroxide and cell permeable fluorescent indicator DCFDA, a cell 
population positive for increased ROS can be segregated from a negative population.  
When DCFDA enters a cell its acetate groups are cleaved by intracellular esterases to 
DCF and oxidation by hydrogen peroxide causes DCF to emit fluorescencent 
wavelengths after excitation.  Fluorescence is due to an increase in the number of pi 
orbital electrons that can be excited, conversion of DCFDA to a planar molecule and 
disruption of conjugate electrons.  DCF has an excitation absorbance at 490 nm, 
therefore when exposed to an Accuri c6 flow cytometer’s 488 nm laser an excitation
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emission occurs at 527 nm which is detected by the FL1 optical filter that has a 
maximum emission detection peak at 533 nm and a high or low detection range 
spanning +/-15 nm from 533 nm.  An increase in positive ROS producing cells will be 
indicated by a shift to the right in the fluorescent peak on a histogram caused by 
excitation of DCF electrons emitting a longer wavelength of energy than cells producing 
a lower amount of ROS or not emitting a fluorescent signal.  A shift to the right indicates 
a higher level of fluorescence in a cell.  To establish the peak fluorescence of DCFDA 
treated cells I compared DCFDA treated MCF7 or IMR90 cells with a second population 
of MCF7 or IMR90 cells treated with DCFDA and hydrogen peroxide.  The shift in 
population of hydrogen peroxide treated cells when compared to dye only cells allowed 
me to determine the fluorescence threshold for positive and negative ROS producing 
cells (Figure 6C and 6D, 8% untreated Vs. 19% H2O2).   
     To assess the best method to treat cells with DCFDA to optimize detection of ROS 
positive cells two different approaches of DCFDA treatment were tested.  In the first 
experiment, MCF7 cells were preloaded with DCFDA and then exposed to hydrogen 
peroxide for 2 hours (Figure 6A and 6B).  The second experiment involved treating MCF7 
cells with Hydrogen peroxide for 2 hours, then loading the cells with DCFDA for 30 
minutes (Figure 6C and 6D).  Following these treatments both sets of cells were rinsed 
with DPBS and then scraped into DPBS for flow cytometry analysis.  From the flow 
cytometry results it appears that cells loaded with DCFDA for 30 minutes after hydrogen 
peroxide exposure produced a slightly higher number of ROS positive cells than when  
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  Preloaded  
    
  DCFDA Exposure After H2O2 
 
Figure 6: Hydrogen Peroxide produces cellular reactive oxygen species levels 
detectable with DCFDA.  MCF7 cells were plated in complete media 24 hours prior to 
treatment.   (A and B) Preloaded with DCFDA (10 μM), followed by treatment of (B) with 
H2O2 (10 μM) for 2 hours.  (C) Treated with H2O2 (10 μM) for 2 hours, followed by 30 
minute DCFDA (10 μM) exposure to (C and D).  Cells were scraped in 1 mL DPBS and 
resuspended into a single cell population before flow cytommetry analysis on an Accuri 
C6 was performed.  (A, B, C and D) Histograms that represent negative and positive ROS 
producing populations.  X-axis represent fluorescence (log scale) and Y-axis represents 
cell count (linear scale). 
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 preloaded with DCFDA for 30 minutes and subsequently exposed to hydrogen peroxide 
treatment.  Pre or post treatment of DCFDA had no effect on the percentage of ROS 
positive cells in the untreated samples (8%; Figures 6A and 6C).  Although both methods 
of DCFDA treatment detected an increase in ROS positive cells, all subsequent 
experiments were performed using the DCFDA post-treatment approach.   
     Through hydrodynamic focusing the flow cytometer passes individual particles or 
cells through the interrogation point containing a laser that determines cell size through 
light scattering or excites fluorophores that emit a fluorescent signal.  If cell damage or 
cell clumping occurs while harvesting the cells it could lead to inaccurate readings 
caused by debris or doublets.  Although debris and doublets can be removed through 
gating this may result in an inaccurate representation of the total population.  To 
determine optimized cell harvesting conditions two methods were tested.  In the first 
approach cells were scraped in DPBS and the cells were vortexed to create a single cell 
population.  Alternatively cells were trypsinized using 1 mL of trypsin.  Trypsinized cells 
were transferred to complete media to inactivate the trypsin, pelleted by centrifugation 
and resuspended in DPBS.  Comparison of the dot plots (Figure 7A) shows that the 
trypsinized cells have a population with a high level of forward and side scatter that is 
absent in the dot plot of the cells scraped in DPBS.  The trypsinized cells have three 
distinct peaks in their histogram compared to one in the DBPS scraped cells (Figure 7B). 
To determine if cell doublets are forming a histogram comparing cell count and side 
scatter pulse width was utilized.  As individual cells pass through the fluidics system the  
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  A               B           C        D           
1    
2     
 
Figure 7: MCF7 cells scraped in DPBS provides a better mechanism to isolate MCF7 
cells for vehicle for analyis by flow cytommetry. 
MCF7 cells were plated at 200k/per well in complete media 24 hours prior to treatment.  
MCF7 cells were treated with DCFDA in DPBS for 30 minutes and scraped in DPBS (Row 
1).  Trypsinized cells were suspended in DMEM + 10% fbs before pelleting and 
resuspending in DPBS (Row 2).  Analysis was performed on an Accuri C6 flow cytometer 
after samples were vortexed. (A) Dot plot analyzing forward scatter and side scatter.  (B) 
Histogram representation of FL1-A  and cell count.  (C) Histogram representation of side 
scatter pulse width and cell count.  (D) Histogram representation of gated single cell 
population (0-100 w) from (C).   
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laser will determine their size using three different pulse parameters which includes 
height, area and width.  Cells moving through the flow cytometer encounter the laser 
one at a time.  When a doublet is encountered it is passed through the fluidics system 
with the doublets orientation parallel to the fluidics system and perpendicular to the 
laser.  The doublets orientation will cause formation of a second peak that will appear 
on the side scatter width and cell count histogram (Figure 7C).  The first peak to the left 
corresponds to single cells and the second peak, which has a higher fluorescence and 
different light scatter will occur to the right on the histogram.  The scraped cells do not 
have a second peak in the side scatter width histogram and the majority of the cells are 
present as single cell events (Figure 7C).  Trypsinized cells form a second peak indicating 
doublets, with more than two thirds of the cell population forming doublets (Figure 7C).  
By gating out the doublets and reanalyzing (Figure 7D), histogram analysis shows that 
there is a higher level of ROS production when cells are trypsinized, indicating 
trypsinization may induce ROS production.  This revealed that cells isolated by scraping 
into DPBS gave interpretable results, whereas the trypsinized cells gave a false ROS 
positive and exhibited clumping or the formation of doublets.  By gating out the 
doublets the trypsinized cells also gave a less accurate interpretation of the data 
because less than a third of the population was represented, whereas the scraped cells 
single cell population represents over 90% of the cells.  Moving forward the method of 
cell isolation was rinsing cells with DPBS after DCFDA treatments and scraping in 1 mL of 
DPBS into 5 mL snap cap tubes, followed by vortexing to create a single cell population 
before flow cytometry analysis. 
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     According to Invitrogen, as well as recent literature, reseeding cells in full serum 
media for a short recovery period after DCFDA exposure gives cellular esterases time to 
cleave acetate groups on the DCFDA molecules and for oxidation of DCF by ROS to cause 
fluorescence (Eruslanov, 2010).  Employing serum free media, in addition to full serum 
media, allowed us to determine if increases in fluorescence are due to growth factors 
stimulating metabolism, or esterasSes present in serum.  To assess ROS levels after a 
period of recovery MCF7 cells were treated with hydrogen peroxide (2 hours) followed 
by DCFDA exposure (30 min) and were allowed to recover in full serum media (Figure 
8A) or serum free media (Figure 8B) for 0, 30 minutes, 1 hour and 2 hours before 
scraping into 1 mL DPBS for flow cytometry analysis.   
     Cells grown in full serum media (Figure 8A) were switched to DPBS while adding 
DCFDA because according to Invitrogen the high level of primary and secondary amines 
in full serum media can hydrolyze DCFDA to its active form which changes its charge and 
impedes its entry into the cell.  MCF7 cells grown in serum free media (SFM) remained 
in SFM upon addition of hydrogen peroxide or DCFDA.  Counter to the literature, the 
level of ROS positive DCFDA fluorescence declines in MCF7 cells as the cells recover in 
full serum media (Figures 8A and 8C).  From the flow cytometry results it appears that 
cells grown in full serum media and exposed to DCFDA for 30 minutes after hydrogen 
peroxide exposure and no recovery period produced a larger number of ROS positive 
cells than when grown in SFM and exposed to the same treatment (Figures 8A and 8B).  
MCF7 cells recovering in full serum media or SFM after treatment with hydrogen 
peroxide and DCFDA exhibit the same trend of ROS positive cells with the highest 
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C) 
 
Figure 8: Allowing DCFDA treated MCF7 cells to recover in complete media after DCFDA 
exposure does not lead to improved ROS positive detection.  MCF7 cells were cultured in full 
serum media over night.  (A) MCF7 cells were treated with H2O2 (10 μM), followed by 30 
minute exposure to DCFDA (10 μM) in DPBS.  The negative control (DCFDA loaded in PBS) was 
only exposed to DCFDA.  Following treatment cells were washed with DPBS and fed with full 
serum media.  Cells were isolated at time points of 0, 30 minutes, 1 hour and 2 hours. (B) MCF7 
cells were treated with H2O2 (10 μM), followed by 30 minute exposure to DCFDA (10 μM) in 
serum free media.  The negative control (MCF7 DCFDA loaded in SFM) was only exposed to 
DCFDA.  Following treatment cells were fed with serum free media.  Cells were isolated at time 
points of 0, 30 minutes, 1 hour and 2 hours by scraping in 1 mL DPBS and resuspended into a 
single cell population before flow cytommetry on an Accuri C6 was performed.  (C) Graphical 
representation of the percentage of ROS positive populations in each treatment condition.  
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increase in ROS positive DCFDA fluorescence occurring with no recovery time, when 
compared to cells receiving DCFDA only.  A gradual decline was observed at each 
isolation point during the recovery period (Figure 8C).  This indicates that MCF7 cells 
grown in full serum media provide higher levels of ROS positive DCFDA fluorescence 
when compared to MCF7 cells grown in serum free media and exposed to the same 
treatments.  Flow cytometry results indicate that recovery after DCFDA exposure is 
unnecessary and actually lowers the amount of ROS positive DCFDA fluorescence.  To 
treat cells in the future I determined optimal DCFDA loading conditions would be 30 
minutes in DPBS, followed immediately by scraping to isolate the cells and analysis by 
flow cytometry.  
     Having established optimized conditions for monitoring ROS positive cells using 
DCFDA, I can set out to examine whether inducing YPEL3 triggered increased ROS within 
human cells.  Initially I tested YPEL3 overexpression by employing MCF7 cells which 
harbored either a tetracycline inducible expression vector that expressed either YPEL3, 
or the LacZ gene.  These cells were grown either in the presence (induced) or absence 
(repressed) of 1 µg/mL tetracycline (Figure 9).  When tetracycline is added to cells 
harboring tetracycline inducible expression vectors gene expression is induced.  The 
dose of 1 µg/mL tetracycline was chosen because it had previously been shown to 
trigger a physiologically relevant 8 fold induction of YPEL3 gene expression (Kelley, 
2010).  Before performing DCFDA/flow cytometry experiments cells were exposed to 
tetracycline and RNA was isolated for quantitative PCR.  MCF7 cells were used to 
normalize expression.  MCF7 cells expressing LacZ were employed to test the integrity of  
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Figure 9: Tetracycline induced YPEL3 expression in MCF7 cells does not lead to higher 
ROS production when compared to LacZ induced MCF7 cells.  A) QPCR results for YPEL3 
expression in MCF7 cells and MCF7 cells with inducible YPEL3 or LacZ grown in the 
presence or absence of 1µg/mL tetracycline for 24 hours after which total RNA was 
isolated.  Y axis represents the relative expression comparing YPEL3 mRNA levels 
normalized to GAPDH mRNA levels.  Error bars represent 95% confidence intervals from 
triplicate PCR reactions analyzing YPEL3 and GAPDH cDNA’s respectively. 
B) Flow cytommetry results for MCF7 cells containing a tetracycline inducible element 
expressing either YPEL3 or LacZ grown in the presence or absence of 1 µg/mL 
tetracycline.  MCF7 cells treated with 10 µM hydrogen peroxide for 2 hours were used 
as a positive control for identifying the ROS positive cell population following DCFDA 
and flow cytommetry.  MCF7 cells treated only with DCFDA dye were used as a ROS 
negative cell population.  Cells were rinsed with DPBS, scraped into DPBS and vortexed 
before analysis by an Accuri C6 flow cytometer.      
C) Bar Graph representing the percent of positive ROS producing cells in each cell 
population (X-axis) analyzed in Figure 9B. 
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the Tet-On system.  The qPCR results show a 4 fold induction of YPEL3 in the YPEL3 tet 
inducible cells when grown in the absence of tetracycline and compared to MCF7 cells 
(Figure 9A).  This indicates that the tetracycline inducible YPEL3 promoter is not 
completely repressed in the Tet-On system which may be caused by the Tet repressor 
protein weakly binding the Tet operon in the absence of tetracycline, or the Tet 
repressor protein not fully inhibiting transcription factors from binding the promoter 
expressing YPEL3.  In the presence of 1 µg/mL tetracycline the YPEL3 inducible cells 
show an 8 fold induction over untreated MCF7 cells and almost twice as much 
expression as YPEL3 inducible cells grown in the absence of tetracycline (Figure 9A).  As 
expected, the lacZ tetracycline inducible cells did not show a change in YPEL3 expression 
regardless of the presence or absence of tetracycline when compared to MCF7 cells 
(Figure 9A).  The tetracycline inducible YPEL3 cells, which have higher YPEL3 gene 
expression than control cells, do not show increased ROS levels when compared to 
MCF7 cells expressing LacZ (Figure 9B and 9C).  This indicates that the overexpression of 
YPEL3 in MCF7 cells does not lead to an increase in ROS.  It should be noted however 
that the YPEL3 and LacZ infected cells show an increase in ROS positive cells when 
compared to MCF7 cells (Figure 9B and 9C).   
     Flow cytommetry results reveal an increase in ROS production in YPEL3 and LacZ 
infected cells independent of tetracycline treatment when compared to MCF7 cells 
(Figure 9C).  The fact that the percentage of ROS positive cells do not increase suggests 
elevation of ROS in cells is the result of the viral infection, the TetR protein, or selection 
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with Zeocin and Blasticidin.  This approach does not provide a good system to assess 
ROS levels due to high levels of ROS detection in all of the infected cells.      
     MCF7 cells harboring a tet inducible expression vector expressing YPEL3 were 
previously shown to have no effect on ROS levels, however leaky expression, or the 
phenotype of MCF7 TetR cells may increase ROS levels.  Therefore an alternative 
method of expressing YPEL3 in MCF7 cells was utilized, as well as exposing the cells to 
an extended period of YPEL3 overexpression to determine if ROS production is a delayed 
response to YPEL3 overexpression.  To determine if MCF7 cells infected with YPEL3 can 
increase ROS levels after infection, immortalized MCF7 cells were infected with 
lentivirus expressing YPEL3, or H-RAS as a positive control (Figure 10).  Cells were 
selected with Zeocin (750 µg/mL) or blasticidin (6 µg/mL) for 12 days, and then 
reseeded for an additional two days before RNA isolation and RT-QPCR were performed 
to monitor YPEL3 levels.  RT-QPCR results show that MCF7 cells infected with lentivirus 
producing YPEL3 showed a 56-fold increase in YPEL3 when compared to uninfected 
MCF7 cells.  Interestingly YPEL3 expressing MCF7 cells also demonstrated an 11-fold 
increase in p21 expression (Figure 10A).  H-RAS infected MCF7 cells possessed a more 
modest 4-fold increase in p21 gene expression and a 4-fold increase in YPEL3 
expression, compared to MCF7 cells.  RAS expression was undetectable after many 
attempts to quantify mRNA levels, however overexpression of RAS has previously been 
shown to increase mRNA expression of p21 through p53 (Agarwal, 2001).  Under this 
assumption it would appear that RAS was expressed, however the level at which it was 
expressed is unknown.     
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Figure 10: MCF7 cells infected with lentivirus expressing YPEL3 show increased gene 
expression of YPEL3.  (A) MCF7 cells were plated in complete media for 24 hours before 
being infected with lentivirus expressing YPEL3 or RAS.  RNA was isolated after 24 hours.   
YPEL3 and p21 mRNA levels were analyzed using RT-PCR normalized to GAPDH mRNA.  
Error bars represent the 95% confidence intervals resulting from triplicate assays for 
both YPEL3 and GAPDH expression.  (B) MCF7 cells were exposed to hydrogen peroxide 
plus DCFDA, or just DCFDA, infected cells were exposed to DCFDA only, and then 
scraped in DPBS.  These samples were vortexed and flow cytommetry was performed.       
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     To assess ROS production by flow cytometry, MCF7 cells infected with lentivirus 
expressing YPEL3, or H-RAS were selected for 12 days with Zeocin (750 µg/mL) or 
blasticidin (6 µg/mL) and then reseeded for an additional 2 days.  Infected MCF7 cells 
were exposed to DCFDA (30 min) followed by scraping to isolate the cells in DPBS (1 mL) 
and then vortexed to ensure a single population for flow cytometry analysis.  Flow 
cytometry results show infection of MCF7 cells with H-RAS and cells treated with 
hydrogen peroxide show an increase in ROS production when compared to MCF7 cells 
(16% and 14% Vs. 5%)  (Figure 10B).  MCF7 cells overexpressing YPEL3 did not show an 
increase in positive ROS producing cells when compared to MCF7 cells (5% Vs. 5%) 
(Figure 10B).   
    Having established that increased level of YPEL3 did not appear to cause an increase 
of ROS in MCF7 breast cancer cells, IMR90 cells were utilized to determine if YPEL3 
senescence in primary fibroblasts is dependent on ROS.  IMR90 primary human diploid 
fibroblast cells were utilized due to their non transformed nature, intact pathways  and 
ability to undergo replicative senescence, as well as oncogene induced senescence.  
IMR90 cell were also utilized because an increase in ROS dependent on YPEL3 may be 
related to the genetic context of the cell.     
     To further investigate any connections between YPEL3 and ROS, IMR90 cells were 
infected with Lentivirus expressing YPEL3, or expressing H-RAS as a positive control 
(Figure 11).  RNA was isolated 2 days post infection and RT-QPCR performed to monitor 
the levels of YPEL3 expression.  RT-QPCR results show that IMR90 cells infected with 
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lentivirus producing YPEL3 showed a 1000 fold increase in YPEL3 when compared to 
uninfected IMR90 cells.  Interestingly YPEL3 expressing IMR90 cells also demonstrated 
an 8 fold increase in p21 expression, but no significant alteration in endogenous RAS 
gene expression (Figure 11A).  H-RAS infected IMR90 cells possessed a more modest 5-
fold increase in RAS gene expression compared to IMR90 cells, as well as a 10-fold 
induction of p21 and a 5-fold induction of YPEL3 (Figure 11A).  
     Using DCFDA and flow cytometry I next examined how YPEL3 and H-RAS infection of 
IMR90 cells impacted ROS activity.  Interestingly, the addition of hydrogen peroxide 
resulted in only a modest increase in ROS positive cells (Figure 11B, 19% Vs. 11%).  
While YPEL3 overexpressing IMR90 cells showed no significant increase in ROS positive 
cells (Figure 11B, 10% Vs. 11%)   The inability of H-RAS to trigger increased ROS activity 
(Figure 11B, 12% Vs. 11%) makes it difficult to conclude whether or not YPEL3 
overexpression is capable of eliciting ROS activity in IMR90 cells.  Since the H-RAS 
infected cells were not selected and showed a more modest level of mRNA induction 
(Figure 11A) it is possible that the failure to detect increased ROS activity as previously 
reported (Moiseeva, 2009) was the result of a low transduction rate or no selection 
applied.  If that assumption is accepted then these results suggest YPEL3 overexpression 
does not lead to increased ROS activity in IMR90 cells.  These results indicate that YPEL3 
does not cause an increase in ROS, and may not trigger senescence in a ROS dependant 
manner in non cancerous IMR90 cells. 
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Figure 11: IMR90 Cells Infected With YPEL3 Expresing Lentivirus Does Not Lead To 
Increased ROS Production.  (A) IMR90 cells were infected with Lentivirus expressing 
YPEL3 or RAS.    RNA was isolated at 24 hours.  YPEL3, RAS and p21 mRNA levels were 
analyzed using RT-PCR normalized to GAPDH mRNA levels.   Error bars represent 95% 
confidence intervals from triplicate PCR reactions analyzing YPEL3, p21, RAS and GAPDH 
cDNA’s respectively.    (B) Flow Cytommetry for IMR90 cells infected with YPEL3 or RAS, 
as well as a negative control exposed to DCFDA (30 Min) and a positive control exposed 
to DCFDA (30 Min) plus the addition of hydrogen peroxide (2 Hr).  Cells were isolated by 
scraping into 1mL DBPS and immediately analyzed by flow cytometry.
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V. Co-Immunoprecipitation of YPEL3-V5 Reveals Potential Bound Proteins. 
   Previous studies have linked increased expression of YPEL3 to cellular senescence 
(Kelley, 2010 and Tuttle, 2011).  However, the mechanism of senescence activation by 
YPEL3 is unknown.  In an attempt to discover putative binding proteins that interact 
with YPEL3 proteins, a Tet-On expression system was utilized followed by co-
immunoprecipitation of YPEL3 and any bound proteins.  The Tet-On system allows 
expression of a gene of interest in the presence of tetracycline, or its derivative 
doxocycline and contains a strong constitutively active cytomegalovirus promoter which 
expresses a tetracycline repressor gene that produces a tetracycline repressor protein 
(TetR).  The TetR protein binds to a tetracycline operon that overlaps with a second 
promoter ligated to an expression gene, which in this case expresses YPEL3.  The second 
promoter is normally repressed by TetR, however in the presence of tetracycline the 
TetR protein is released from the tet operon and transcription of YPEL3 along with a V5 
epitope tag occurs.  The V5 epitope tag allows us to co-immunoprecipitate YPEL3 by 
binding it to anti V5 agarose beads and precipitating it from whole cell extracts.  
Activation of the second promoter in the presence of tetracycline will cause 
amplification of YPEL3-V5 protein levels, which can be extracted upon lysis of the cells.  
In order to perform a co-immunoprecipitation the conditions under which cells are lysed 
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must be optimized to conserve protein interactions and decrease the chance of protein 
degradation.  By utilizing anti V5 agarose beads YPEL3-V5 can be extracted along with 
any YPEL3 linked proteins.  The protein sequences of the co-immunoprecipitated 
proteins were determined by liquid chromatography tandem mass spectrometry 
analysis (LC/MS/MS) at Oregon Health and Science University.  To analyze proteins by 
LC/MS/MS, proteins are first enzymatically digested into peptides at Oregon Health 
Science University and introduced into a mass spectrometer via a liquid chromatography 
system.  Once inside the mass spectrometer the peptides are fragmented to produce 
MS/MS spectra.  The patterns of fragmentation are matched against theoretical spectra 
from a protein database and the sequence of each individual peptide is derived.  Scoring 
algorithms and statistical tools are then used to determine their identification and 
quantity.        
     To determine if we were able to extract YPEL3 by co-immunoprecipitation, MCF7 
cells that had previously been infected on two separate occasions with a Tet-On system 
followed by infection with lentivirus expressing YPEL3 fused to a V5 epitope tag were 
grown in complete media containing 10 μg/mL of tetracycline for 24 hours to induce 
YPEL3 gene expression.  The two separate infections were identified as Y3O, to indicate 
cells created by Kelly Miller, and Y3N to indicate cells created by Dr. Steven Berberich.  
Alternatively MCF7 cells were infected with a Tet-On system lacking YPEL3 or a V5 tag 
(MCF7 TetR) were also subject to 10 μg/mL of tetracycline for 24 hours.  Post 
tetracycline exposure, MCF7 cells were scraped into 5 mL of DBPS and pelleted.  After 
freezing the cells (-80oC minimum of 24 hours) they were thawed and lysed in 5 volumes 
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of lysis buffer components and centrifuged to separate soluble and insoluble material.  
A Bradford assay was performed on the extracts to determine the protein 
concentration.  Protein extract (50 mg) was diluted in lysis buffer (10 mL) with the 
addition of anti V5 agarose beads (40µg) and inverted overnight at 4oC before being 
subjected to 3 washes to remove unbound proteins.  Covalently bound proteins were 
eluted from the V5 agarose beads in 6X SDS loading dye and proteins were separated on 
an SDS-Page gradient gel by electrophoresis.  After Western transfer, the blot was 
probed for YPEL3 with a primary monoclonal V5 antibody (1:5000 for 4 hours) and a 
secondary goat anti mouse antibody conjugated to horseradish peroxidase (1:2500).  
Chemiluminesence analysis of the probed blot showed the presence of YPEL3 in the Y3O 
and Y3N lanes between the 15-25 kDa molecular weight markers, indicating YPEL3-V5 
was eluted in the co-immunoprecipitation (Figure 12).  As expected, a band was not 
present in the extracts not expressing YPEL3-V5 (MCF7 TetR), as indicated by the 
absence of a band in lane 5 between 15-25 kDa.  The higher molecular weight bands 
indicate V5 antibody binding to human proteins lacking V5 antibody.  This could have 
been caused by insufficient blocking or too high of a primary or secondary antibody 
concentration. Moving forward growth of the YPEL3 inducible cells known as YPEL3 New 
or Y3N were discontinued in favor of the cells known as YPEL3 Old, or Y3O, due to a 
higher level YPEL3 expression determined by qPCR after Y3O and Y3N were treated with 
10µg/mL tetracycline (data not shown).  In addition the protocol was optimized by 
exposing the beads to an additional 3 washes in lysis buffer to remove unbound  
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Figure 12:  Extraction of YPEL3-V5 by co-immunoprecipitation.  
     MCF7 cells harboring a tetracycline expression vector expressing YPEL3-V5 (Y3O or 
Y3N), or not expressing YPEL3 (TetR) were grown in DMEM minus tetracycline until 
reaching 80% confluency.  Tetracycline was added to the media (10 μg/mL of media) for 
24 hours and the cells were scraped in5mL DPBS for pelleting.  Cells were frozen then 
lysed (50mM Tris pH 8.0, 5mM EDTA, 150nM NaCl, 0.5% Nonident p-40, 1mM 
phenylmethanesulfonylfluoride (Sigma), 1mM Dithiothreitol (Sigma) and Protease 
Inhibitor Coctail (Sigma)) and centrifuged to remove insoluble material.  Protein extracts 
(40 mg) were co-immunoprecipitated and eluted for separation on an SDS page gel by 
electrophoresis.  Proteins were transferred by Western analysis and probed with 
primary V5 antibody (1:5000 for 4 hours) and secondary goat anti mouse antibody 
conjugated to horseradish peroxidase (1:2500).  Molecular weights were determine by 
comparing to the molecular weight marker (M).  Lane 2 is blank (B).  Arrow is pointing to 
YPEL3-V5 tagged proteins.  
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proteins.  A colloidal blue stain of each fraction taken after a wash indicated the absence 
of unbound proteins after 6 washes (data not shown).  All co-immunoprecipitation 
beads from this point were washed 6 times in lysis buffer.  
     The ability to extract YPEL3-V5 is crucial for the discovery of potential YPEL3 bound 
proteins.  After extraction and separation any bands occurring in the Y3O lane that does 
not occur in the TetR lane could be potential binding proteins of YPEL3 that would be 
excised and analyzed by mass spectrometry.  To visualize these potential bands a highly 
sensitive method of protein detection known as silver staining was implemented.  To 
determine the best silver stain method that is mass spectrometry compatible, three 
silver staining methods were compared, each using an identical amount of protein.  
Protein for this analysis was obtained either from the whole cell extracts of MCF7 cells 
(MCF7 TetR and Y3O) after treatment with tetracycline, or protein was eluted off of anti 
V5 agarose beads after co-immunoprecipitation of whole cell extracts (Figure 13).  The 
Bio-Rad method developed distinct bands with little background noise and would be the 
preferred method of choice; however this silver stain method is incompatible with mass 
spectrometry due to the use of a strong oxidizer (Figure 13A). Method 2 had a high level 
of background noise and either revealed very faint yellow bands, or was not sensitive 
enough to pick up bands that appeared in the other 2 methods (Figure 13B).  The lanes 
appeared either clear or slightly yellow in method 2.  Method 3 was nearly as free of 
background noise as the Bio Rad kit method and showed an equivalent number of 
visible bands (Figure 13C).  This method is also compatible with mass spectrometry and 
yields a high level of protein recovery for analysis because it does not cause cross linking  
 
66 
 
A)                                                     B)                                C)     
                             
                      * 
 
 
 
 
 
 
 
 
67 
 
Figure 13:  Comparison of three Silver Stain Methods.  
SDS-Page protein gels were fixed in 40% methanol and 5% acetic acid overnight on a 
shaker.  (A) Method 1 Bio-Rad Silver stain kit (Bio-Rad). (B) Method 2 10% 
glutaraldehyde, 200 nM dithiothreitol, .1% silver nitrate.  (C) Method 3 sodium 
thiosulfate, .1% silver nitrate.  (A, B, C)  Develop with .04% formalin plus 2% sodium 
carbonate.  Stop development in 1% acetic acid.  The molecular weight marker is 
indicated by (M). Whole cell extracts were indicated as Tet-On (T) and Tet-On expressing 
YPEL3 (Y3).  The samples labeled (Tf and Y3f) were insoluble protein fractions not bound 
to V5 agarose beads.   
* The gel in method 1 is on the same scale as method 2 and 3 however it appears 
smaller due it tearing during removal from the electrophoresis apparatus.  The majority 
of the gel that was lost was below the SDS dye front. 
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of proteins and utilizes a weak oxidizer so silver ions can be easily removed before mass 
spectrometry.  All subsequent experiments use silver staining method 3. 
     To isolate potential proteins interacting with the YPEL3 protein, whole cell extracts 
(TetR and Y3) of tetracycline treated cells (10 µg/mL) were co-immunoprecipitated and 
bound protein was subsequently eluted by a competitively binding V5 peptide (30 min).  
After the first elution, the anti V5 agarose beads were exposed to 1X SDS loading dye to 
elute any additional proteins still bound to the beads (BF).  The eluted fraction (EF) and 
BF fraction were separated on an SDS page gel and analyzed by silver staining (Figure 
14).  The wells loaded with EF appear to be absent of any detectable protein, indicating 
elution by competing V5 peptide may not be the best method of elution or the elution 
should have been for a longer period of time.  The bead fraction (BF) had two bands 
appear in the Y3 lane that were absent in the Tet lane.  Excision of the bands, followed 
by Liquid chromatography-tandem mass spectrometry analysis revealed a larger band 
near 140 kDa (Band 1) contained Mov10 (Putative Helicase), HNRL1 (Heterogeneous 
nuclear ribonucleoprotein U like protein), Lima1 (Lim domain and actin binding protein) 
and RBM14 (RNA binding protein 14) (Table 2).  Interestingly, these proteins were not 
found in any of the other analyzed bands.  In addition to Band 1, another band near 60 
kDa was extracted and analyzed by mass spectrometry (Figure 14).  The second band 
(Band 2) contained two proteins, CARM-1 (Histone Arginine Methyl Transferase) and 
FA98A (isoform belonging to FAAM98A protein family), not found in any of the other 
analyzed bands (Table 2). 
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Figure 14: Secondary elution revealing 2 bands in the YPEL3 only lane.  Band 1 was 
between 140kDA-100kDA and band 2 between 70kDa-50kDA.  MCF7 TetR and Y3O cell 
extracts (40 mg) were co-immunoprecipitated with anti V5 agarose beads and YPEL3-V5 
was competitively eluted from the beads after being washed 6 times to remove non 
specifically bound proteins (EF).  The beads were subsequently exposed to SDS loading 
dye to elute any remaining proteins (Beads).  The eluted proteins were separated on an 
SDS Page gel by electrophoresis and stained with silver stain.  Two bands (indicated by 
arrows) were excised and incubated twice for 30 minutes in 1.0 mL of solution made of 
acetonitrile and 100 mM ammonium bicarbonate mixed in a 1:1 ratio.  After the second 
washing the mixture was fully removed and the extracted bands were dried in a speed 
vac. 
Band 1 
Band 2 
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     Under the assumption that the eluted fraction had a low level of protein due to the 
inability of the competing peptide to efficiently compete off YPEL3-V5 from the beads in 
30 minutes, the eluted fractions were concentrated from 160 µL to 20 µL.  This also 
removed any proteins below 3000 Da in size due to the concentrator’s molecular weight 
cutoff.  Silver stain analysis revealed a band above 50 kDa in the Y3 lane (Band 3) 
however no additional bands were discovered (Figure 15, EFc).  Mass spectrometry 
analysis of this band determined that the majority of the protein was caused by 
contamination (Table 2).  The bead fraction was separated by electrophoresis on an SDS 
page gel and stained by silver stain (Figure 15 Beads), which showed a similar pattern to 
the bead extraction in figure 14.   
     To assess if an alternative method of eluting proteins from anti V5 agarose beads will 
give us a higher protein yield, the extracts of treated (10 µg/mL tetracycline) MCF7 cells 
(TetR and Y30) were co-immunoprecipitated by anti V5 agarose beads, however protein 
was eluted by heating (75oC) the samples for 5 minutes in 1X SDS running buffer (Figure 
16).  Silver staining was utilized to locate variations in bands between the two samples.  
After developing the gel, thick bands appeared in each lane above the 50 kDa molecular 
weight marker and two additional bands appeared at 35 kDa and 25 kDa in each lane.  
The only variation that occurred was a darker band in the YPEL3 expressing cells near 25 
kDa.  This band was also visible in MCF7 (TetR) cells, but much more faint.  The 
difference in band intensity does not appear to be loading related because the other 
bands in each lane exhibit the same level of intensity.  Extraction of the band and  
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Figure 15: Band 3 located between the 50kDa and 70kDa molecular weight markers.   
     MCF7 TetR and Y3O cell extracts (40 mg) were co-immunoprecipitated with anti V5 
agarose beads and YPEL3-V5 was competitively eluted from the beads after being 
washed 6 times to remove non specifically bound proteins (EFc).  The EF fractions were 
concentrated from 160µL to 20 µL and SDS loading dye was added.  The beads were 
subsequently exposed to SDS loading dye to elute any remaining proteins (Beads).  The 
eluted proteins were separated on an SDS Page gel by electrophoresis and stained with 
silver stain.  One band (indicated by arrow) was excised and shook twice for 30 minutes 
in 1.0 mL of solution made of acetonitrile and 100 mM ammonium bicarbonate mixed in 
a 1:1 ratio.  After the second washing the mixture was fully removed and the extracted 
bands were dried in a speed vac.  
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Figure 16: The fourth extracted band from immunoprecipitated material appeared 
between the 25kDa and 35kDa molecular weight bands.       MCF7 TetR and Y3O cell 
extracts (68.4 mg) were co-immunoprecipitated with anti V5 agarose beads and YPEL3-
V5 was eluted in 1X SDS running buffer after the beads were washed 6 times (EF).  The 
EF fractions were concentrated from 200µL to 20 µL and SDS loading dye was added.  
The beads were subsequently exposed to SDS loading dye to elute any remaining 
proteins (Beads).  The eluted proteins were separated on an SDS Page gel by 
electrophoresis and stained with silver stain.  One band (indicated by arrow) was 
excised and shook twice for 30 minutes in 1.0 mL of solution made of acetonitrile and 
100 mM ammonium bicarbonate mixed in a 1:1 ratio.  After the second washing, the 
mixture was fully removed, and the extracted bands were dried in a speed vac. 
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subsequent mass spectrometry analysis did not determine the presence of any potential 
YPEL3 binding proteins (Table 2). 
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 Table 2: Liquid chromatography tandem mass spectrometry analysis (LC/MS/MS)  
Description Accession MW 
Band 
1 
Band 
2 
Band 
3 
Band 
4 
REVERSED. REV_Q8WZ42 3816189 2 0 0 1 
Titin OS=Homo sapiens GN=TTN 
PE=1 SV=2 TITIN_HUMAN 3816189 0 2 1 1 
Mucin-5B OS=Homo sapiens 
GN=MUC5B PE=1 SV=3 MUC5B_HUMAN 596341 0 0 2 0 
Desmoplakin OS=Homo sapiens 
GN=DSP PE=1 SV=3 DESP_HUMAN 331775 2 8 15 7 
REVERSED. REV_O15417 314520 2 1 0 0 
Hornerin OS=Homo sapiens 
GN=HRNR PE=1 SV=2 HORN_HUMAN 282391 1 1 3 1 
Probable G-protein coupled receptor 
179 OS=Homo sapiens GN=GPR179 
PE=2 SV=2 GP179_HUMAN 257364 0 0 2 0 
WD repeat-containing protein 90 
OS=Homo sapiens GN=WDR90 
PE=1 SV=2 WDR90_HUMAN 187438 1 0 2 1 
REVERSED. REV_P02452 138943 0 0 0 2 
Splicing factor 3B subunit 3 
OS=Homo sapiens GN=SF3B3 PE=1 
SV=4 SF3B3_HUMAN 135578 4 0 0 0 
Myosin-Ib OS=Homo sapiens 
GN=MYO1B PE=1 SV=3 MYO1B_HUMAN 131986 10 0 0 0 
Myosin-Ic OS=Homo sapiens 
GN=MYO1C PE=1 SV=4 MYO1C_HUMAN 121683 42 0 0 0 
Myosin-Id OS=Homo sapiens 
GN=MYO1D PE=1 SV=2 MYO1D_HUMAN 116203 12 0 0 0 
Probable ATP-dependent RNA 
helicase DHX36 OS=Homo sapiens 
GN=DHX36 PE=1 SV=2 DHX36_HUMAN 114761 2 0 0 0 
Desmoglein-1 OS=Homo sapiens 
GN=DSG1 PE=1 SV=2 DSG1_HUMAN 113749 2 2 7 1 
Putative helicase MOV-10 OS=Homo 
sapiens GN=MOV10 PE=1 SV=2 MOV10_HUMAN 113672 5 0 0 0 
Alpha-actinin-4 OS=Homo sapiens 
GN=ACTN4 PE=1 SV=2 ACTN4_HUMAN 104855 2 0 0 0 
Desmocollin-1 OS=Homo sapiens 
GN=DSC1 PE=1 SV=2 DSC1_HUMAN 99988 1 2 5 2 
Heterogeneous nuclear 
ribonucleoprotein U-like protein 1 
OS=Homo sapiens GN=HNRNPUL1 
PE=1 SV=2 HNRL1_HUMAN 95740 32 0 0 0 
Interleukin enhancer-binding factor 3 
OS=Homo sapiens GN=ILF3 PE=1 
SV=3 ILF3_HUMAN 95339 2 0 0 0 
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Description Accession MW 
Band 
1 
Band 
2 
Band 
3 
Band 
4 
Pre-rRNA-processing protein TSR1 
homolog OS=Homo sapiens 
GN=TSR1 PE=1 SV=1 TSR1_HUMAN 91811 2 0 0 0 
Transcription intermediary factor 1-
beta OS=Homo sapiens GN=TRIM28 
PE=1 SV=5 TIF1B_HUMAN 88551 4 0 0 0 
LIM domain and actin-binding protein 
1 OS=Homo sapiens GN=LIMA1 
PE=1 SV=1 LIMA1_HUMAN 85227 9 0 0 0 
Polymeric immunoglobulin receptor 
OS=Homo sapiens GN=PIGR PE=1 
SV=4 PIGR_HUMAN 83285 1 3 8 0 
REVERSED. REV_P33897 82938 0 0 2 0 
Junction plakoglobin OS=Homo 
sapiens GN=JUP PE=1 SV=3 PLAK_HUMAN 81746 0 4 8 3 
Caprin-1 OS=Homo sapiens 
GN=CAPRIN1 PE=1 SV=2 CAPR1_HUMAN 78367 3 0 0 0 
Lactotransferrin OS=Homo sapiens 
GN=LTF PE=1 SV=6 TRFL_HUMAN 78183 3 10 38 2 
Polyubiquitin-C OS=Homo sapiens 
GN=UBC PE=1 SV=2 UBC_HUMAN 77030 1 2 2 2 
Protein-glutamine gamma-
glutamyltransferase E OS=Homo 
sapiens GN=TGM3 PE=1 SV=4 TGM3_HUMAN 76633 1 1 5 3 
Uncharacterized protein C6orf222 
OS=Homo sapiens GN=C6orf222 
PE=2 SV=1 CF222_HUMAN 71931 2 0 0 1 
RNA-binding protein 14 OS=Homo 
sapiens GN=RBM14 PE=1 SV=2 RBM14_HUMAN 69493 23 0 0 0 
SERUM ALBUMIN PRECURSOR 
[Homo sapiens]. CONT_017 69368 6 5 20 8 
Serum albumin OS=Homo sapiens 
GN=ALB PE=1 SV=2 ALBU_HUMAN 69368 6 5 20 8 
SERUM ALBUMIN PRECURSOR 
[Bos taurus]. CONT_016 69271 6 4 8 6 
Probable ATP-dependent RNA 
helicase DDX5 OS=Homo sapiens 
GN=DDX5 PE=1 SV=1 DDX5_HUMAN 69149 1 2 0 0 
Keratin, type II cytoskeletal 1 
OS=Homo sapiens GN=KRT1 PE=1 
SV=6 K2C1_HUMAN 66040 111 178 314 177 
(S43646) cytokeratin 2, CK 2 [human, 
epidermis, Peptide, 645 aa]. CONT_064 65912 53 80 136 73 
KERATIN, TYPE II CYTOSKELETAL 
2 EPIDERMAL (CYTOKERATIN 2E) 
(K2E) (CK 2E) [Homo sapiens]. CONT_072 65866 53 80 136 73 
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Description Accession MW 
Band 
1 
Band 
2 
Band 
3 
Band 
4 
Histone-arginine methyltransfeRASe 
CARM1 OS=Homo sapiens 
GN=CARM1 PE=1 SV=3 CARM1_HUMAN 65855 0 8 0 0 
albumin [Bos primigenius taurus]. CONT_015 65798 6 4 8 6 
keratin, 67K type II cytoskeletal 
[Homo sapiens]. CONT_143 65495 80 114 208 112 
Semenogelin-2 OS=Homo sapiens 
GN=SEMG2 PE=1 SV=1 SEMG2_HUMAN 65445 1 1 3 0 
Keratin, type II cytoskeletal 2 
epidermal OS=Homo sapiens 
GN=KRT2 PE=1 SV=2 K22E_HUMAN 65434 57 87 145 78 
keratin, 65K type II cytoskeletal 
[Homo sapiens]. CONT_142 64449 3 6 16 14 
Keratin, type II cytoskeletal 3 
OS=Homo sapiens GN=KRT3 PE=1 
SV=3 K2C3_HUMAN 64418 3 6 16 14 
Keratinocyte proline-rich protein 
OS=Homo sapiens GN=KPRP PE=1 
SV=1 KPRP_HUMAN 64137 1 4 14 3 
Tumor necrosis factor receptor 
superfamily member 8 OS=Homo 
sapiens GN=TNFRSF8 PE=1 SV=1 TNR8_HUMAN 63748 0 2 0 0 
Keratin, type II cytoskeletal 5 
OS=Homo sapiens GN=KRT5 PE=1 
SV=3 K2C5_HUMAN 62379 22 36 68 54 
Keratin, type I cytoskeletal 9 
OS=Homo sapiens GN=KRT9 PE=1 
SV=3 K1C9_HUMAN 62065 59 104 185 93 
Keratin, type II cytoskeletal 1b 
OS=Homo sapiens GN=KRT77 PE=1 
SV=3 K2C1B_HUMAN 61902 12 22 33 16 
Prolyl 4-hydroxylase subunit alpha-1 
OS=Homo sapiens GN=P4HA1 PE=1 
SV=2 P4HA1_HUMAN 61050 0 2 0 0 
KERATIN, TYPE II CYTOSKELETAL 
6F (CYTOKERATIN 6F) (CK 6F) 
(K6F KERATIN) [Homo sapiens]. CONT_133 60068 26 42 87 70 
Keratin, type II cytoskeletal 6B 
OS=Homo sapiens GN=KRT6B PE=1 
SV=5 K2C6B_HUMAN 60068 26 42 87 70 
KERATIN, TYPE II CYTOSKELETAL 
6A (CYTOKERATIN 6A) (CK 6A) 
(K6A KERATIN) [Homo sapiens]. CONT_129 60046 24 35 72 70 
Keratin, type II cytoskeletal 6A 
OS=Homo sapiens GN=KRT6A PE=1 
SV=3 K2C6A_HUMAN 60046 24 35 72 70 
Catalase OS=Homo sapiens 
GN=CAT PE=1 SV=3 CATA_HUMAN 59757 0 0 2 0 
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Description Accession MW 
Band 
1 
Band 
2 
Band 
3 
Band 
4 
Keratin, type II cytoskeletal 73 
OS=Homo sapiens GN=KRT73 PE=1 
SV=1 K2C73_HUMAN 58924 3 6 11 6 
SWI/SNF-related matrix-associated 
actin-dependent regulator of 
chromatin subfamily D member 2 
OS=Homo sapiens GN=SMARCD2 
PE=1 SV=3 SMRD2_HUMAN 58922 0 7 0 0 
Keratin, type I cytoskeletal 10 
OS=Homo sapiens GN=KRT10 PE=1 
SV=6 K1C10_HUMAN 58828 63 91 172 80 
SWI/SNF-related matrix-associated 
actin-dependent regulator of 
chromatin subfamily D member 1 
OS=Homo sapiens GN=SMARCD1 
PE=1 SV=2 SMRD1_HUMAN 58234 0 2 0 0 
Keratin, type II cytoskeletal 79 
OS=Homo sapiens GN=KRT79 PE=1 
SV=2 K2C79_HUMAN 57837 5 11 28 26 
Keratin, type II cytoskeletal 4 
OS=Homo sapiens GN=KRT4 PE=1 
SV=4 K2C4_HUMAN 57286 6 10 13 7 
KERATIN, TYPE II CYTOSKELETAL 
4 (CYTOKERATIN 4) (K4) (CK4) 
[Homo sapiens]. CONT_119 57266 6 10 13 7 
keratin 10, type I, epidermal [Homo 
sapiens]. CONT_046 57248 50 75 136 64 
Keratin, type II cytoskeletal 78 
OS=Homo sapiens GN=KRT78 PE=1 
SV=2 K2C78_HUMAN 56867 4 7 13 9 
Protein FAM98A OS=Homo sapiens 
GN=FAM98A PE=1 SV=1 FA98A_HUMAN 55402 0 10 0 0 
Keratin 8 - human [Homo sapiens]. CONT_103 53705 4 11 8 4 
Keratin, type II cytoskeletal 8 
OS=Homo sapiens GN=KRT8 PE=1 
SV=7 K2C8_HUMAN 53705 4 11 8 4 
KERATIN, TYPE I CYTOSKELETAL 
12 (CYTOKERATIN 12) [Homo 
sapiens]. CONT_165 53512 6 7 11 3 
Keratin, type I cytoskeletal 12 
OS=Homo sapiens GN=KRT12 PE=1 
SV=1 K1C12_HUMAN 53512 6 7 11 3 
RNA-binding protein FUS OS=Homo 
sapiens GN=FUS PE=1 SV=1 FUS_HUMAN 53427 2 1 1 2 
Keratin, type I cytoskeletal 14 
OS=Homo sapiens GN=KRT14 PE=1 
SV=4 K1C14_HUMAN 51562 27 39 60 45 
Keratin, type I cytoskeletal 16 
OS=Homo sapiens GN=KRT16 PE=1 
SV=4 K1C16_HUMAN 51269 22 27 52 38 
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Description Accession MW 
Band 
1 
Band 
2 
Band 
3 
Band 
4 
type I keratin 16 [human, epidermal 
keratinocytes, Peptide, 473 aa]. CONT_156 51239 22 27 52 38 
Keratin, type II cytoskeletal 80 
OS=Homo sapiens GN=KRT80 PE=1 
SV=2 K2C80_HUMAN 50526 1 0 5 1 
Putative elongation factor 1-alpha-like 
3 OS=Homo sapiens GN=EEF1A1P5 
PE=5 SV=1 EF1A3_HUMAN 50186 0 0 2 0 
Elongation factor 1-alpha 1 
OS=Homo sapiens GN=EEF1A1 
PE=1 SV=1 EF1A1_HUMAN 50142 0 0 2 0 
Keratin, type I cytoskeletal 27 
OS=Homo sapiens GN=KRT27 PE=1 
SV=2 K1C27_HUMAN 49823 6 13 19 9 
Keratin, type I cytoskeletal 13 
OS=Homo sapiens GN=KRT13 PE=1 
SV=4 K1C13_HUMAN 49589 5 15 22 9 
KH domain-containing, RNA-binding, 
signal transduction-associated protein 
1 OS=Homo sapiens GN=KHDRBS1 
PE=1 SV=1 KHDR1_HUMAN 48228 0 3 0 0 
KERATIN, TYPE I CYTOSKELETAL 
17 (CYTOKERATIN 17) (K17) (CK 
17) (39.1) (VERSION 1) [Homo 
sapiens]. CONT_094 48107 15 21 35 44 
Keratin, type I cytoskeletal 17 
OS=Homo sapiens GN=KRT17 PE=1 
SV=2 K1C17_HUMAN 48107 15 21 35 44 
Serpin B12 OS=Homo sapiens 
GN=SERPINB12 PE=1 SV=1 SPB12_HUMAN 46277 0 2 1 0 
Serpin B3 OS=Homo sapiens 
GN=SERPINB3 PE=1 SV=2 SPB3_HUMAN 44566 0 1 5 0 
Actin, cytoplasmic 2 OS=Homo 
sapiens GN=ACTG1 PE=1 SV=1 ACTG_HUMAN 41794 2 7 49 2 
Actin, cytoplasmic 1 OS=Homo 
sapiens GN=ACTB PE=1 SV=1 ACTB_HUMAN 41738 2 7 49 2 
Fructose-bisphosphate aldolase A 
OS=Homo sapiens GN=ALDOA 
PE=1 SV=2 ALDOA_HUMAN 39421 0 0 2 0 
Annexin A1 OS=Homo sapiens 
GN=ANXA1 PE=1 SV=2 ANXA1_HUMAN 38715 0 0 3 0 
Annexin A2 OS=Homo sapiens 
GN=ANXA2 PE=1 SV=2 ANXA2_HUMAN 38605 0 2 6 3 
Ig alpha-1 chain C region OS=Homo 
sapiens GN=IGHA1 PE=1 SV=2 IGHA1_HUMAN 37656 4 0 6 2 
Ig alpha-2 chain C region OS=Homo 
sapiens GN=IGHA2 PE=1 SV=3 IGHA2_HUMAN 36527 2 0 4 1 
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Description Accession MW 
Band 
1 
Band 
2 
Band 
3 
Band 
4 
Glyceraldehyde-3-phosphate 
dehydrogenase OS=Homo sapiens 
GN=GAPDH PE=1 SV=3 G3P_HUMAN 36054 2 4 8 4 
Arginase-1 OS=Homo sapiens 
GN=ARG1 PE=1 SV=2 ARGI1_HUMAN 34736 1 1 2 1 
Zinc-alpha-2-glycoprotein OS=Homo 
sapiens GN=AZGP1 PE=1 SV=2 ZA2G_HUMAN 34260 1 1 4 1 
40S ribosomal protein SA OS=Homo 
sapiens GN=RPSA PE=1 SV=4 RSSA_HUMAN 32855 0 0 2 0 
Tropomyosin beta chain OS=Homo 
sapiens GN=TPM2 PE=1 SV=1 TPM2_HUMAN 32852 0 0 2 0 
Tropomyosin alpha-3 chain 
OS=Homo sapiens GN=TPM3 PE=1 
SV=1 TPM3_HUMAN 32820 0 0 2 0 
Tropomyosin alpha-1 chain 
OS=Homo sapiens GN=TPM1 PE=1 
SV=2 TPM1_HUMAN 32710 0 0 2 0 
Tropomyosin alpha-4 chain 
OS=Homo sapiens GN=TPM4 PE=1 
SV=3 TPM4_HUMAN 28523 0 0 2 0 
Caspase-14 OS=Homo sapiens 
GN=CASP14 PE=1 SV=2 CASPE_HUMAN 27681 1 1 4 3 
Polyubiquitin-B OS=Homo sapiens 
GN=UBB PE=1 SV=1 UBB_HUMAN 25763 1 2 2 2 
BETA CASEIN PRECURSOR [Bos 
taurus]. CONT_021 25108 2 0 4 0 
ALPHA-S1 CASEIN PRECURSOR 
[Bos taurus]. CONT_019 24530 1 1 7 1 
TRYPSIN PRECURSOR [Sus scrofa]. CONT_010 24410 87 76 64 77 
Peroxiredoxin-2 OS=Homo sapiens 
GN=PRDX2 PE=1 SV=5 PRDX2_HUMAN 21893 0 3 0 2 
Ubiquitin-40S ribosomal protein S27a 
OS=Homo sapiens GN=RPS27A 
PE=1 SV=2 RS27A_HUMAN 17966 1 2 2 2 
Prolactin-inducible protein OS=Homo 
sapiens GN=PIP PE=1 SV=1 PIP_HUMAN 16573 1 1 4 0 
Lysozyme C OS=Homo sapiens 
GN=LYZ PE=1 SV=1 LYSC_HUMAN 16538 4 5 8 2 
Cystatin-S OS=Homo sapiens 
GN=CST4 PE=1 SV=3 CYTS_HUMAN 16215 1 0 2 0 
Proline-rich protein 4 OS=Homo 
sapiens GN=PRR4 PE=1 SV=3 PROL4_HUMAN 15098 0 2 1 0 
Galectin-7 OS=Homo sapiens 
GN=LGALS7 PE=1 SV=2 LEG7_HUMAN 15076 0 0 2 1 
Ubiquitin-60S ribosomal protein L40 
OS=Homo sapiens GN=UBA52 PE=1 
SV=2 RL40_HUMAN 14729 1 2 2 2 
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Description Accession MW 
Band 
1 
Band 
2 
Band 
3 
Band 
4 
Protein S100-A9 OS=Homo sapiens 
GN=S100A9 PE=1 SV=1 S10A9_HUMAN 13243 0 5 6 5 
Ig kappa chain C region OS=Homo 
sapiens GN=IGKC PE=1 SV=1 IGKC_HUMAN 11610 1 2 7 1 
Dermcidin OS=Homo sapiens 
GN=DCD PE=1 SV=2 DCD_HUMAN 11285 12 19 27 24 
Protein S100-A8 OS=Homo sapiens 
GN=S100A8 PE=1 SV=1 S10A8_HUMAN 10836 4 2 8 5 
Promega trypsin artifact 5 K to R 
mods (2239.1, 2914)(1987, 2003). CONT_005 5561 15 16 14 18 
angiotensin I [Homo sapiens]. CONT_009 1297 17 14 14 11 
 
 
 
Table 2: Liquid chromatography-tandem mass spectrometry analysis  
     Analysis of 4 isolated bands reveals potential proteins that may bind to YPEL3.  
Emphasis on certain proteins was based on their number of hits in each sample, as well 
as their molecular weight corresponding to the excised bands.  Proteins listed in normal 
font are not specific to a sample, do not correlate with the molecular weight of the 
excised band, have a very low hit number, or may not impact senescence.   The band 
numbers above the protein hit number columns correlate to the excised bands.  
Proteins highlighted blue correlate to a high level of protein specificity for a certain 
band.  Analysis was performed at Oregon Health and Science University. Abreviations: 
OS = Organism, GN= Gene Name, PE= Evidence at the Protein Level, SV= Sequence 
Version. 
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VI.Discussion 
YPEL3 gene expression is repressed in prostate cancer cells by testosterone. 
     Estrogen has been implicated in estrogen receptor positive breast cancer as a pro 
growth steroid hormone leading to cell proliferation.  A connection was established 
between estrogen and YPEL3 when the removal of estrogen, from estrogen receptor 
positive breast cancer cells, caused an induction of YPEL3 gene expression (Tuttle, 
2011).  This discovery linked estrogen to the senescence inducing YPEL3 gene and 
demonstrated a potential mechanism by which selective estrogen receptor modulators 
can block breast cancer proliferation.   
     To build off of this previous work we expanded the research to include LnCAP 
prostate cancer cells, as well as utilizing testosterone in an attempt to determine if this 
steroid hormone also regulates YPEL3 expression.  It was discovered that testosterone 
signals proliferation in androgen receptor positive prostate cancer cells, which indicates 
testosterone may have the same effect on YPEL3 expression in prostate cancer cells, as 
estrogen does on ER+ breast cancer cells.  
My first objective was to show the removal of hormones induce YPEL3 gene expression, 
indicating that its repression is dependent on steroid hormones.  Like estrogen receptor 
positive breast cancer cells, growing LnCAP cells in CSS media devoid 
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of steroid hormones and quantifying YPEL3 mRNA levels we were able to determine that 
steroid hormones inhibit YPEL3 gene expression in LnCAP cells.  Growing LnCAP cells in 
CSS media with the addition of testosterone treatments repressed YPEL3 gene 
expression at doses as low as 2 nM when compared to LnCAP cells grown in CSS media 
only.   As expected the known testosterone target gene PSA was induced in the 
presence of testosterone when compared to LnCAP cells grown in CSS media only.  Cells 
that were harvested 24 hours after treatment did not appear to have any significant 
differences in density or morphology at the time of harvest indicating a need for 
additional experiments.  Further experiments would need to be conducted to determine 
if the removal of testosterone leads to YPEL3 dependent cellular senescence.  The 
length of time that 10 nM of testosterone can impact YPEL3 expression was assessed 
and it was determined that at a time point after 24 hours and between 48 hours PSA 
expression begins to decline, however YPEL3 is still maximally repressed at 48 hours.  
This is due to testosterone having a half life between 2 and 4 hours which may indicate 
that at a lower dose, testosterone can repress YPEL3, but induce PSA as well.  
Quantification of the estrogen target gene pS2’s mRNA expression showed no change in 
expression, indicating that testosterone is not being converted to estrogen in LnCAPs 
even though LnCAPs are reported to express aromatase (Ellem, 2004).  Androgen 
ablation causes growth arrest in androgen receptor positive prostate cancer cells (Agus, 
1999).  Implications for these findings are a potential mechanism by which selective 
androgen receptor modulators antagonize androgen receptors which block repression 
of YPEL3 and induce growth arrest.  However, additional experiments would need to be 
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completed to confirm this link.  Knockdown of the androgen receptor in testosterone 
treated LnCAP cells grown in CSS media followed by YPEL3 gene expression analysis 
would provide us with the knowledge that testosterone is repressing YPEL3 expression 
in either an androgen receptor dependent, or independent manner.  If YPEL3 gene 
repression is dependent on the presence of testosterone and the androgen receptor, it 
would be beneficial to determine if senescence is dependent on YPEL3 expression in 
LnCAP prostate cancer cells.  This could be accomplished by measuring β-galactosidase 
activity in LnCAP cells grown in full serum media or CSS (+ or – testosterone), and 
knocking down the androgen receptor in another set grown in CSS (+ or – testosterone).  
If the β-galactosidase test is positive for senescence in the cells grown in CSS only this 
indicates senescence is dependent on YPEL3 in the absence of testosterone or the 
androgen receptor.  Therapeutic effects could then be tested by administering selective 
androgen receptor modulators to the LnCAP cells.  Another potential target that may 
regulate YPEL3 in LnCAPs is ER-β, which is the major estrogen receptor expressed in 
prostate cells, due to its ability to suppress growth progression through increased levels 
of p21 (Pravettoni, 2006).   
YPEL3 gene expression is repressed in breast cancer cells following the addition of 
testosterone. 
     Since testosterone has been shown to have a growth inhibiting effect on breast 
cancer cells, we tested the ability of testosterone to regulate YPEL3 expression as a 
potential mechanism of growth inhibition.  We were able to show that in MCF7 breast 
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cancer cells testosterone treatment increases YPEL3 gene expression levels.  
Interestingly, we were able to show that the increase of YPEL3 gene expression is dose 
dependent and also depends on the dose of estrogen present, indicating these 
hormones may antagonize each other’s ability to regulate YPEL3 gene expression.  
These findings suggest a mechanism and also an argument for administering a cocktail 
of testosterone agonists or testosterone derivatives combined with selective estrogen 
receptor modulators, as a therapy for endocrine responsive breast cancers.  To 
determine if senescence is testosterone and androgen receptor dependent, this can be 
accomplished by measuring β-galactosidase activity in MCF7 cells grown in complete 
media or CSS (+ or – testosterone) and comparing this to MCF7 cells containing a 
knocking down of the androgen receptor grown, also in CSS (+ or – testosterone). 
      Further analysis of YPEL3 gene expression in the presence of steroid hormones could 
move toward analyzing the effects of progesterone.  When bound to estrogen, estrogen 
receptor α can increase gene expression of the progesterone receptor (Kastner, 1990).  
This increase in progesterone receptor expression plus the addition of progesterone can 
either, evoke cell cycle progression, or cause cellular differentiation (Alkhalaf, 2003).  
Transient pulses of progesterone regulate these two counteracting functions in breast 
cancer cells by evoking cell cycle progression for the first cycle and arresting cells at the 
G1 /S checkpoint of the second cycle to allow differentiation (Owen, 1998).  
Differentiation continues until progesterone is degraded and the process repeats 
(Owen, 1998).  Progesterone accomplishes this by initially upregulating p21 gene 
expression through the transcription factor sp1 (Owen, 1998).  This biphasic effect of 
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progesterone is antagonized by the ability of the ER-α which suppresses p21 activity 
(Brekman, 2011).  This pathway appears to have the potential to respond to endocrine 
therapy and it has an important link to estrogen receptors, indicating its use as a 
potential biomarker. 
Increased levels of YPEL3 gene expression does not trigger increased ROS levels 
     Reactive oxygen species play a major signaling role in the event of cellular stresses.  
Replicative senescence, DNA damage response and oncogene mediated senescence all 
lead to the activation of p53 which is capable of activating p21 and causing growth 
arrest.  Increased expression of p21 increases the cellular levels of ROS in a feedback 
mechanism to stabilize p53 activation and cause the cell to enter permanent senescence 
(Passos, 2010).  Another target gene of p53 that mediates cellular senescence is YPEL3 
(Kelley, 2010). 
     Conditions were first optimized to detect hydrogen peroxide (H2O2) in MCF7 cells 
which allows us to determine the threshold that separates cells exhibiting DCFDA 
fluroescence (positive) from those that do not (negative).  This assessment of conditions 
includes treatments of MCF7 cells with hydrogen peroxide (2 Hr), followed by DCFDA 
exposure (30 Min), rather than preloading DCFDA at the time of peroxide treatment.  
Lower levels of fluorescence in the preloaded MCF7 cells could potentially be caused by 
oxidation of DCFDA outside of the cells which changes its charge and causes it to 
become impermeable to the cell membrane.  
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     Trypsinizing cells for flow cytometry analysis causes an increased level of ROS 
production and clumping when compared to scraping in DPBS.  This may be caused by 
an extended length of time that the cells were exposed to trypsin, however scraping in 
DPBS was used in future isolations.  Allowing the MCF7 cells a period of exposure to full 
serum media after hydrogen peroxide and DCFDA exposure should in theory cause 
higher levels of DCFDA detections due to reestablishing growth factors in the media that 
signal metabolism. Counter to this rational, MCF7 cells recovering in full serum media or 
serum free media actually showed the same pattern of decline in DCFDA fluorescence 
detection when compared.  Declining fluorescence could be attributed to the ability of 
catalase to convert hydrogen peroxide to oxygen and water, which would leave less to 
oxidize DCFDA to DCF, or it may be caused by the ability of fluorescent DCF to leak out 
of live cells and be washed away in DPBS at the time of harvest (Chen, 2003). 
     Overexpression of YPEL3 in MCF7 cells controlled by a Tet-On system showed by RT-
qPCR an increase in YPEL3 gene expression in the absence of tetracycline and an even 
higher increase when tetracycline was present when compared to MCF7 cells.  This 
increase in YPEL3 expression was not seen in Tet-On cells expressing LacZ.   Treatment 
with DCFDA showed an increase in ROS levels when compared to MCF7 cells in the 
absence of tetracycline, however this level remained the same when tetracycline was 
added.  This would suggest that the lower level of YPEL3 expression in the cells growth 
without tetracycline treatment is sufficient to maximally activate ROS production.  
However the LacZ expressing Tet-On MCF7 cells expressed the same levels of ROS 
production indicating that a component of the Tet-On system may lead to ROS 
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production.  This increase in ROS could also be caused by the cells reaching confluency 
and senescing, or cell culture conditions. However, this is unlikely due to the MCF7 cells 
not having high fluorescence indicating ROS because all cells were subject to the same 
conditions.     
     Since the Tet-On system left us with potentially ambiguous results regarding ROS 
production, alternatively, MCF7 cells were infected with lentivius expressing YPEL3, 
selected, and hydrogen peroxide levels were measured 2 days post selection.  Although 
a 56-fold induction of YPEL3 gene expression was shown, we were unable to detect an 
increase in the levels of hydrogen peroxide, relative to MCF7 cells, by flow cytometry 
analysis, as well as by fluorescent microscopy of DCFDA treated cells counterstained 
with Hoechst stain.  We were able to see an increase in ROS levels by flow cytometry 
and fluorescent imaging when MCF7 cells express H-RAS.  However this could be caused 
by p21 since RAS levels were undetermined by RT-QPCR analysis. 
     To assess the potential of YPEL3 everexpresion to produce ROS in another cell line, 
IMR90 cells were utilized.  IMR90 primary human diploid fibroblast cells were utilized 
due to their non transformed nature and ability to undergo replicative senescence, as 
well as oncogene induced senescence.  Assessing IMR90 cells expressing YPEL3 for ROS 
production, we see that there is not an increase in ROS levels when compared to 
untreated MCF7 cells.  Surprisingly we did not see an increase in ROS levels when IMR90 
cells were infected with H-RAS, however, this could be related to using cells that were 
not selected after infection.  This would indicate a low level of infection, which would 
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correlate to the low levels of RAS induction seen by RT-QPCR.  Surprisingly YPEL3 and H-
RAS infected cells exhibited 8 and 10 fold increases of p21 respectively.  H-RAS 
expression also caused a 5 fold increase in YPEL3 expression.  
 Potential Proteins that Interact With YPEL3 Proteins. 
     Since YPEL3 may function as a tumor suppressor activating senescence, it is beneficial 
to discover putative proteins which interact with YPEL3 proteins.  By inducing expression 
of YPEL3-V5 in MCF7 cells and lysing the cells to make whole cell extracts, we were able 
to extract YPEL3 and any potential YPEL3 bound proteins by co-immunoprecipitation 
with anti V5 agarose beads.  Analysis of co-immunoprecipitated proteins by western 
blot analysis with V5 antibody showed YPEL3 bands between 15-25 kDa in the expected 
lanes indicating we were able to extract the 18 kDa YPEL3-V5 protein from the whole 
cell extracts (Figure 12).   
     After optimization of silver staining methods we were able to extract 4 bands not 
found in MCF7 cells.  The bands were analyzed by Liquid chromatography-mass 
spectrometry, compared against a database of protein sequences and the number of 
times the sequence appears in the extracted band determines its relevance.  After 
elimination of known contaminating bands and reverse sequences from the results we 
ended up with 79 potential proteins; however some of these may still may be caused by 
contamination during handling of the samples.  Of the four extracted bands analyzed by 
mass spectrometry, 3 of the 4 provided useable results, with band 3 composed of 
mostly contamination.  Two of the bands had relatively high hit numbers for proteins 
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that correspond to the molecular weight where the protein bands were excised from 
the gels.  Gel 1 had bands extracted near 140 kDa as well as 70 kDa.  Potential proteins 
that had high hit levels and may correspond to the 140 kDa band includes MOV10, 
HNRL1, and RBM14.  A potential protein corresponding to the 70 kDa band was CARM1.  
The inability to detect more proteins in bands 1 and 2, and the inability to detect 
proteins in bands 3 and 4 could be due to rapid degradation of YPEL3, or due to low 
affinity or transient transactions that are not conserved outside of a cells physiological 
state.  
     Expression of co-activator associated arginine methyl transferase (CARM-1) had 
previously been shown in estrogen receptor positive MCF7 cells to slow the rate cell 
growth in an estrogen dependent manner by associating with estrogen receptor α and 
upregulating expression of the negative cell cycle regulators p21 and p27  (Al-Dhaheri, 
2011).  CARM-1’s ability to increase p21 and p27 causes growth arrest by blocking cell 
cycle entry into S phase (Al-Dhaheri, 2011)  Interestingly it was also found to relieve 
estrogen dependent repression of approximately 56% of estrogen repressed genes (Al-
Dhaheri, 2011).  This implicates CARM-1 as having a potential role in inhibiting estrogen 
receptor α’s ability to repress YPEL3 which would trigger growth arrest. 
     MOV10 is a putative RNA helicase which has been implicated as a novel telomere 
associated protein that is essential for telomerase activity in transformed cells (Wang, 
2010).  Telomerase activity will extend the length of telomeres and inhibit replicative 
senescence in cancer cells.  RNA helicases can also modulate the structure of critical 
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RNA molecules and make them available for processing which leads to protein 
expression (Wang, 2010).  If YPEL3 has the ability to bind to MOV10 it could potentially 
inhibit its ability to recruit telomerase to the telomeres which would lead to telomere 
degradation and replicative senescence (Wang, 2010).   
     HNRL1 and RNA binding protein 14 have functions that have not been fully elucidated 
and very little is known about them. HNRL1 is a splice variant of N-Methyl-D-aspartate 
receptor.  N-Methyl-D-aspartate receptor belongs to a subcategory of post-synaptic 
ionotropic glutamate receptors which are important for sodium and calcium ion entry 
into the neurons. Overstimulation of these receptors has been associated with chronic 
neurodegenerative conditions due to elevations of calcium concentrations in neurons 
(Camacho, 2002). 
     RNA binding protein 14 has been shown to interact with RISC loading complex 
subunit TARBP2 (Melo, 2009).  Inactivation of TARBP2 causes destabilization of the 
DICER1 protein which leads to tumor formation and defects in the expression of mature 
miRNA, while activation of TARBP2 inhibits tumors (Melo, 2009).  
Conclusion 
       The goals of this thesis were to expand on the impact that hormones have on YPEL3 
gene expression, to determine if YPEL3 has an impact on reactive oxygen species 
generation and to identify potential proteins that bind to YPEL3 proteins.  It was 
demonstrated that testosterone regulation of YPEL3 is tissue type dependent. 
Testosterone has an inhibitory effect on YPEL3 gene expression in androgen receptor 
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positive prostate cancer cells and triggers expression of the YPEL3 gene in androgen 
receptor positive breast cancer cells.   Also demonstrated were the counteracting 
effects on YPEL3 gene expression by combined testosterone and estrogen treatments.  
Progesterone did not have an effect on YPEL3 gene expression. 
     Increasing YPEL3 levels did not demonstrate an increase in reactive oxygen species 
levels in breast cancer cells, or primary diploid human fibroblasts, indicating YPEL3 must 
mediate cellular senescence in a ROS independent manner.  Co-immunoprecipitation 
and LC/MS/MS analysis of proteins found 79 potential binding proteins, however this 
was narrowed down to four potential proteins due to their high frequency levels, their 
molecular weight corresponding to the size of the excised band and having a potential 
senescence function.  The potential proteins discovered were MOV10, HNRL1, RBM14 
and CARM1.  Taken together, these findings aim to provide mechanisms of YPEL3 gene 
expression that may be targeted in endocrine therapy, as well as identifying potential 
YPEL3 binding proteins that may help us understand the function of YPEL3 better and 
facilitate the discovery of how it causes cellular senescence.          
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